Podcasts about DOI

  • 1,459PODCASTS
  • 5,036EPISODES
  • 32mAVG DURATION
  • 2DAILY NEW EPISODES
  • Sep 15, 2025LATEST

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about DOI

Show all podcasts related to doi

Latest podcast episodes about DOI

Frankly Speaking About Family Medicine
Trying to Quit—Effective Cessation Strategies for Teens Who Vape - Frankly Speaking Ep 450

Frankly Speaking About Family Medicine

Play Episode Listen Later Sep 15, 2025 17:32


Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-450 Overview: Use of e-cigarettes has increased significantly over the last several years and their popularity continues to grow, notably among adolescents and young adults. Recent evidence indicates that the majority of teens and young adults who vape consider quitting; however, nicotine addiction has historically been difficult to treat in this population. Join us as we discuss the prevalence of vaping, associated harms, and new evidence on the effectiveness of varenicline on cessation.  Episode resource links: CDC https://www.cdc.gov/tobacco/e-cigarettes/youth.html Evins, A. E., Cather, C., Reeder, H. T., Evohr, B., Potter, K., Pachas, G. N., Gray, K. M., Levy, S., Rigotti, N. A., Iroegbulem, V., Dufour, J., Casottana, K., Costello, M. A., Gilman, J. M., & Schuster, R. M. (2025). Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA, e253810. Advance online publication. https://doi.org/10.1001/jama.2025.3810 Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2024;1(1):CD010216. Published 2024 Jan 8. doi:10.1002/14651858.CD010216.pub8 Park-Lee E, Ren C, Sawdey MD, et al. Notes from the Field: E-Cigarette Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1387–1389. DOI: http://dx.doi.org/10.15585/mmwr.mm7039a4external icon;  Tuisku A, Rahkola M, Nieminen P, Toljamo T. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(8):915–921. doi:10.1001/jamainternmed.2024.1822 Zhang, L., Gentzke, A., Trivers, K. F., & VanFrank, B. (2022). Tobacco Cessation Behaviors Among U.S. Middle and High School Students, 2020. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 70(1), 147–154. https://doi.org/10.1016/j.jadohealth.2021.07.011 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Pri-Med Podcasts
Trying to Quit—Effective Cessation Strategies for Teens Who Vape - Frankly Speaking Ep 450

Pri-Med Podcasts

Play Episode Listen Later Sep 15, 2025 17:32


Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-450 Overview: Use of e-cigarettes has increased significantly over the last several years and their popularity continues to grow, notably among adolescents and young adults. Recent evidence indicates that the majority of teens and young adults who vape consider quitting; however, nicotine addiction has historically been difficult to treat in this population. Join us as we discuss the prevalence of vaping, associated harms, and new evidence on the effectiveness of varenicline on cessation.  Episode resource links: CDC https://www.cdc.gov/tobacco/e-cigarettes/youth.html Evins, A. E., Cather, C., Reeder, H. T., Evohr, B., Potter, K., Pachas, G. N., Gray, K. M., Levy, S., Rigotti, N. A., Iroegbulem, V., Dufour, J., Casottana, K., Costello, M. A., Gilman, J. M., & Schuster, R. M. (2025). Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial. JAMA, e253810. Advance online publication. https://doi.org/10.1001/jama.2025.3810 Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev. 2024;1(1):CD010216. Published 2024 Jan 8. doi:10.1002/14651858.CD010216.pub8 Park-Lee E, Ren C, Sawdey MD, et al. Notes from the Field: E-Cigarette Use Among Middle and High School Students — National Youth Tobacco Survey, United States, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1387–1389. DOI: http://dx.doi.org/10.15585/mmwr.mm7039a4external icon;  Tuisku A, Rahkola M, Nieminen P, Toljamo T. Electronic Cigarettes vs Varenicline for Smoking Cessation in Adults: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(8):915–921. doi:10.1001/jamainternmed.2024.1822 Zhang, L., Gentzke, A., Trivers, K. F., & VanFrank, B. (2022). Tobacco Cessation Behaviors Among U.S. Middle and High School Students, 2020. The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 70(1), 147–154. https://doi.org/10.1016/j.jadohealth.2021.07.011 Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Aging-US
AI Tools Uncover New Link Between Idiopathic Pulmonary Fibrosis and Aging

Aging-US

Play Episode Listen Later Sep 11, 2025 3:44


BUFFALO, NY — September 11, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled “AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging.” In this study, researchers Fedor Galkin, Shan Chen, Alex Aliper, Alex Zhavoronkov, and Feng Ren from Insilico Medicine used artificial intelligence (AI) to investigate the similarities between idiopathic pulmonary fibrosis (IPF), a severe lung disease, and the aging process. Their findings show that IPF is not simply accelerated aging, but a distinct biological condition shaped by age-related dysfunction. This insight may lead to a new approach in how scientists and clinicians treat this complex disease. IPF mainly affects individuals over the age of 60. It causes scarring of lung tissue, making it harder to breathe and often leading to respiratory failure. Current treatments can slow the disease but rarely stop or reverse its progression. The researchers used AI to identify shared biological features between aging and fibrosis, finding new potential targets for therapy. The team developed a “proteomic aging clock” based on protein data from more than 55,000 participants in the UK Biobank. This AI-driven tool accurately measured biological age and found that patients with severe COVID-19, who are at increased risk for lung fibrosis, also showed signs of accelerated aging. This suggests that fibrosis leaves a detectable biological trace, supporting the use of aging clocks in studying age-related diseases. “For aging clock training, we used the UK Biobank collection of 55319 proteomic Olink NPX profiles annotated with age and gender.” They also developed a custom AI model, ipf-P3GPT, to compare gene activity in aging lungs versus those with IPF. Although some genes were active in both, many showed opposite behavior. In fact, more than half of the shared genes had inverse effects. This means IPF does not just speed up aging but also disrupts the body's normal aging pathways. The study identified unique molecular signatures that distinguish IPF from normal aging. While both involve inflammation and tissue remodeling, IPF drives more damaging changes to lung structure and repair systems. This difference could guide the development of drugs that specifically target fibrosis without affecting normal aging. By combining AI with large-scale biological data, the study also introduces a powerful toolset for examining other age-related conditions such as liver and kidney fibrosis. These models may support personalized treatments and expand understanding of the relationships between aging and disease, opening new directions for therapy development. DOI - https://doi.org/10.18632/aging.206295 Corresponding author - Alex Zhavoronkov - alex@insilico.com Abstract video - https://www.youtube.com/watch?v=24lX2lHbt7o Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206295 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, IPF, generative AI, transformer, proteomics To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Stuff You Missed in History Class
William Firth Wells and Mildred Weeks Wells

Stuff You Missed in History Class

Play Episode Listen Later Sep 10, 2025 46:09 Transcription Available


Husband-and-wife team William Firth Wells and Mildred Weeks Wells conducted research that had the potential to make a big difference in the safety of indoor air. But it didn’t really have a significant impact on public health. Research: Associated Press. “Super-Oyster Is On its Way to Dinner Table Bigger and Better Bivalve Sports Pedigree.” 3/13/1927. https://www.loc.gov/resource/sn84020064/1927-03-13/ed-1/?sp=14 “Brought Back to Texas.” The Houston Semi-Weekly Post. 12/26/1889. https://www.newspapers.com/image/1196039760/ Decatur Daily Review. “Scientists Fight Flu Germs with Violet Ray.” 7/30/1936. https://www.newspapers.com/image/94335504/ Evening Star. “Scientific Trap-shooter.” 6/26/1937. https://www.loc.gov/resource/sn83045462/1937-06-26/ed-1/?sp=7&q=William+Firth+Wells&r=0.668,0.557,0.438,0.158,0 Fair, Gordon M. and William Weeks Wells. “Method and Apparatus for Preventing Infection.” U.S. Patent 2,198,867. https://ppubs.uspto.gov/api/pdf/downloadPdf/2198867 Hall, Dominic. “New Center for the History of Medicine Artifact - Wells Air Centrifuge.” Harvard Countway Library. https://countway.harvard.edu/news/new-center-history-medicine-artifact-wells-air-centrifuge “Incubator Is Now Oyster Nurse.” Washington Times. 10/1/1925. https://www.loc.gov/resource/sn84026749/1925-10-01/ed-1/?sp=12 Lewis, Carol Sutton. “Mildred Weeks Wells’s Work on Airborne Transmission Could Have Saved Many Lives—If the Scientific Establishment Listened.” Lost Women of Science Podcast. Scientific American. 5/22/2025. https://www.scientificamerican.com/article/a-public-health-researcher-and-her-engineer-husband-found-how-diseases-can/ Library and Archives Team. “William Firth Wells and Mildred Weeks Wells.” Washington College. https://www.washcoll.edu/people_departments/offices/miller-library/archives-special-collections/archives-blog/Wells%20papers.php Molenti, Megan. “The 60-Year-Old Scientific Screwup That Helped Covid Kill.” Wired. 5/13/2021. https://www.wired.com/story/the-teeny-tiny-scientific-screwup-that-helped-covid-kill/ Perkins JE, Bahlke AM, Silverman HF. Effect of Ultra-violet Irradiation of Classrooms on Spread of Measles in Large Rural Central Schools Preliminary Report. Am J Public Health Nations Health. 1947 May;37(5):529-37. PMID: 18016521; PMCID: PMC1623610. Randall, Katherine and Ewing, E. Thomas and Marr, Linsey and Jimenez, Jose and Bourouiba, Lydia, How Did We Get Here: What Are Droplets and Aerosols and How Far Do They Go? A Historical Perspective on the Transmission of Respiratory Infectious Diseases (April 15, 2021). Available at SSRN: https://ssrn.com/abstract=3829873 Riley, Richard L. “What Nobody Needs to Know About Airborne Infection.” American Journal of Respiratory and Critical Care Medicine. Volume 163, Issue 1. https://www.atsjournals.org/doi/10.1164/ajrccm.163.1.hh11-00 Simon, Clea. “Did a socially awkward scientist set back airborne disease control?” The Harvard Gazette. 3/7/2025. https://news.harvard.edu/gazette/story/2025/03/did-a-socially-awkward-scientist-set-back-airborne-disease-control/ “Texas State News.” McKinney Weekly Democrat-Gazette. 4/17/1890. https://www.newspapers.com/image/65385350/ WELLS MW, HOLLA WA. VENTILATION IN THE FLOW OF MEASLES AND CHICKENPOX THROUGH A COMMUNITY: Progress Report, Jan. 1, 1946 to June 15, 1949, Airborne Infection Study, Westchester County Department of Health. JAMA. 1950;142(17):1337–1344. doi:10.1001/jama.1950.02910350007004 WELLS MW. VENTILATION IN THE SPREAD OF CHICKENPOX AND MEASLES WITHIN SCHOOL ROOMS. JAMA. 1945;129(3):197–200. doi:10.1001/jama.1945.02860370019006 WELLS WF, WELLS MW. AIR-BORNE INFECTION. JAMA. 1936;107(21):1698–1703. doi:10.1001/jama.1936.02770470016004 WELLS WF, WELLS MW. AIR-BORNE INFECTION: SANITARY CONTROL. JAMA. 1936;107(22):1805–1809. doi:10.1001/jama.1936.02770480037010 Wells, W F, and M W Wells. “Measurement of Sanitary Ventilation.” American journal of public health and the nation's health vol. 28,3 (1938): 343-50. doi:10.2105/ajph.28.3.343 Wells, William Firth and Gordon Maskew Fair. Viability of B. coli Exposed to Ultra-Violet Radiation in Air.Science82,280-281(1935).DOI:10.1126/science.82.2125.280.b Wells, William Firth and Mildred Weeks Wells. Measurement of Sanitary Ventilation American Journal of Public Health and the Nations Health 28, 343_350, https://doi.org/10.2105/AJPH.28.3.343 Zimmer, Carl. “Air-Borne: The Hidden History of the Life We Breathe.” Dutton. 2025. See omnystudio.com/listener for privacy information.

Beekeeping Today Podcast
[Bonus] Short - Dr. Dewey Caron: Fat Bees and Overwintering Success

Beekeeping Today Podcast

Play Episode Listen Later Sep 10, 2025 19:57


In this BTP Short, Dr. Dewey Caron shares another of his “audio postcards,” this time exploring the critical role of fat bees—also known as diutinus bees—in helping colonies survive winter. Dewey explains how these long-lived worker bees differ from their summer sisters, with enlarged fat bodies, higher protein reserves, and lower juvenile hormone levels, all tied to the key blood protein vitellogenin. Drawing on published research papers, Dewey highlights how environmental cues such as declining pollen, temperature, and daylight trigger the production of winter bees, and how clustering helps colonies thermoregulate through the cold months. He emphasizes that strong, heavy colonies going into winter are far more likely to survive than weak or light ones. For beekeepers, Dewey stresses the importance of continuous Varroa control throughout the season, fall feeding to ensure sufficient carbohydrate and protein stores, and combining weaker units when necessary. He also discusses drone eviction, stock influences, and climate change modeling that suggests warmer falls may disrupt the balance of winter bee production and survival. This episode provides science-based insights and practical recommendations to help beekeepers communicate with their colonies—ensuring not only fat bees, but fat, well-prepared colonies for overwintering success. Websites and Links mention in the episode: Döke, Mehmet A. M. Frazier, and C.  Grozinger, 2015 “Overwintering honey bees: biology and management,” Current Opinion in Insect Science. Mehmet Ali Döke, Christina M. Grozinger. 2017. Pheromonal control of overwintering physiology and success in honey bees (Apis mellifera, L.) Döke, Mehmet Ali, CM McGrady, M. Otieno, CM Grozinger, M Frazier. 2019. Colony size, rather than geographic origin of stocks, predicts overwintering success in honey bees (Hymenoptera: Apidae) in the Northeastern United States. J. Econ. Entomology 112 (2), 525-533, DOI: 10.1093/jee/toy377 Stephanie Feliciano-Cardona, †Mehmet Ali Döke, Janpierre Ale man,Jose Luis Agosto-Rivera. Christina M. Grozinger and Tugrul Giray 2020. Honey Bees in the Tropics Show Winter Bee-Like Longevity in Response to Seasonal Dearth and Brood Reduction. Front. Ecol. Evol., 8.  https://doi.org/10.3389/fevo.2020.571094 Somerville, Doug (2005) Fat Bees Skinny Bees, A manual on honey bee nutrition for beekeepers., Australia. Available on the Web at https://www.agrifutures.com.au/wp-content/uploads/publications/05-054.pdf   https://rirdc.infoservices.com.au/downloads/05-054 Kirti Rajagopalan, Gloria DeGrandi-Hoffman, Matthew Pruett, Vincent P. Jones, Vanessa Corby-Harris, Julien Pireaud, Robert Curry, Brandon Hopkins & Tobin D. Northfield. 2024. Warmer autumns and winters could reduce honey bee overwintering survival with potential risks for pollination services. Scientific Reports volume 14, Article number: 5410 (2024) For homework Ashley L. St. Clair , Nathanael J. Beach, Adam G. Dolezal. 2022.  Honey bee hive covers reduce food consumption and colony mortality during overwintering. Plos One. https://doi.org/10.1371/journal.pone.0266219  SBGM videos:  https://mail.google.com/mail/u/0/#inbox/FMfcgzQcpKmXBhglCpthGSBzvHVLlSfp   Brought to you by Betterbee – your partners in better beekeeping. ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com Copyright © 2025 by Growing Planet Media, LLC

Herpetological Highlights
235 Magnetoad Goes Home

Herpetological Highlights

Play Episode Listen Later Sep 9, 2025 34:06


Toads continue to amaze us - this time they are using their sense of the Earth's magnetic field to find their way home. But how important this sense is for cane toads as they travel home from long journeys, and how much are they relying on their sense of smell, was a mystery, until a clever new study tested the toads. Then we briefly touch on how pythons digest bones so successfully. Main Paper References: Fernandez RC, Sotelo MI. 2025. A toad's journey home: towards elucidating the neural and sensory basis of amphibian navigation. Proceedings of the Royal Society B: Biological Sciences 292. DOI: 10.1098/rspb.2025.0525. Shaykevich DA, Pareja-Mejía D, Golde C, Pašukonis A, O'Connell LA. 2025. Neural and sensory basis of homing behaviour in the invasive cane toad, Rhinella marina. Proceedings of the Royal Society B: Biological Sciences 292:20250045. DOI: 10.1098/rspb.2025.0045. Other Mentioned Papers/Studies: Lignot J-H, Pope RK, Secor SM. 2025. Diet-dependent production of calcium- and phosphorus-rich ‘spheroids' along the intestine of Burmese pythons: identification of a new cell type? Journal of Experimental Biology 228:jeb249620. DOI: 10.1242/jeb.249620. Other Links/Mentions: Starr M. 2025.New Cell Discovered in Pythons Allows Them to Completely Digest Bones. Available at https://www.sciencealert.com/new-cell-discovered-in-pythons-allows-them-to-completely-digest-bones (accessed August 25, 2025). Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com

Proteomics in Proximity
From self-driving cars to self-caring people

Proteomics in Proximity

Play Episode Listen Later Sep 9, 2025 45:00


Welcome to the Olink® Proteomics in Proximity podcast!  Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  World Health Organization (2003). Adherence to long-term therapies: evidence for action (PDF). Geneva: World Health Organisation. ISBN 978-92-4-154599-0 Research articles and news·       Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Studyhttps://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientifics-Olink-Platform-Selected-for-Worlds-Largest-Human-Proteome-Study/default.aspx·       Hamilton Se-Hwee Oh et al 2025. Plasma proteomics links brain and immune system aging with healthspan and longevityhttps://www.nature.com/articles/s41591-025-03798-1. Nature Medicine (2025)·       Song, Y., Abuduaini, B., Yang, X. et al. Identification of inflammatory protein biomarkers for predicting the different subtype of adult with tuberculosis: an Olink proteomic study. Inflamm. Res. 74, 60 (2025). https://doi.org/10.1007/s00011-025-02020-9·       Ferhan Qureshi et al 2023. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteomics clinical application 2023·       Dhindsa, R.S., Burren, O.S., Sun, B.B. et al. Rare variant associations with plasma protein levels in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06547-xhttps://www.nature.com/articles/s41586-023-06547-x·       Sun, B.B., Chiou, J., Traylor, M. et al.  Plasma proteomic associations with genetics and health in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06592-6 https://www.nature.com/articles/s41586-023-06592-6 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac495/6676779·       Eldjarn GH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023 Oct;622(7982):348-358. doi: 10.1038/s41586-023-06563-xhttps://www.nature.com/articles/s41586-023-06563-x#Sec44·        Carrasco-Zanini et al 2024 Proteomic prediction of common and rare diseases. https://www.nature.com/articles/s41591-024-03142-z . NatureMedicine volume 30,  pages2489–2498 (2024)·       Watanabe K, Wilmanski T, Diener C, et al. Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention.https://www.nature.com/articles/s41591-023-02248-0·       Petrera A, von Toerne C, Behlr J, et al. Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling. (2020) Journal of Proteome Research, https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.0c00641·       Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens. Kardell O, von Toerne C, Merl-Pham J, König AC, Blindert M, Barth TK, Mergner J, Ludwig C, Tüshaus J, Eckert S, Müller SA, Breimann S, Giesbertz P, Bernhardt AM, Schweizer L, Albrecht V, Teupser D, Imhof A, Kuster B, Lichtenthaler SF, Mann M, Cox J, Hauck SM. J Proteome Res. 2024 Jan 5;23(1):117-129. doi: 10.1021/acs.jproteome.3c00473. Epub 2023 Nov 28. PMID: 38015820 https://pubs.acs.org/doi/10.1021/acs.jproteome.3c00473·       Wei, S., Shen, R., Lu, X. et al. Integrative multi-omics investigation of sleep apnea: gut microbiome metabolomics, proteomics and phenome-wide association study. Nutr Metab (Lond) 22, 57 (2025). https://doi.org/10.1186/s12986-025-00925-0·       Liu, L., Li, M., Qin, Y. et al. Childhood obesity and insulin resistance is correlated with gut microbiome serum protein: an integrated metagenomic and proteomic analysis. Sci Rep 15, 21436 (2025). https://doi.org/10.1038/s41598-025-07357-z·       Zhang, Xiaotao et al.Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. eBioMedicine, Volume 98, 104873 (2023.).  10.1016/j.ebiom.2023.104873·      &nb...

Aphasia Access Conversations
Episode 132: Group Treatment with Dr. Liz Hoover

Aphasia Access Conversations

Play Episode Listen Later Sep 9, 2025 40:39


Lyssa Rome is a speech-language pathologist in the San Francisco Bay Area. She is on staff at the Aphasia Center of California, where she facilitates groups for people with aphasia and their care partners. She owns an LPAA-focused private practice and specializes in working with people with neurogenic communication disorders. She has worked in acute hospital, skilled nursing, and continuum of care settings. Prior to becoming an SLP, Lyssa was a public radio journalist, editor, and podcast producer. In this episode, Lyssa Rome interviews Liz Hoover about group treatment for aphasia.   Guest info Dr. Liz Hoover is a clinical professor of speech language and hearing sciences and the clinical director of the Aphasia Resource Center at Boston University. She holds board certification from the Academy of Neurologic Communication Disorders and Sciences, or ANCDS, and is an ASHA fellow. She was selected as a 2024 Tavistock Trust for Aphasia Distinguished Scholar, USA and Canada. Liz was a founding member of Aphasia Access and served on the board for several years. She has 30 years of experience working with people with aphasia and other communication disorders across the continuum of care. She's contributed to numerous presentations and publications, and most of her work focuses on the effectiveness of group treatment for individuals with aphasia.   Listener Take-aways In today's episode you will: Describe the evidence supporting aphasia conversation groups as an effective interventions for linguistic and psychosocial outcomes. Differentiate the potential benefits of dyads versus larger groups in relation to client goals. Identify how aphasia severity and group composition can influence treatment outcomes.   Edited transcript Lyssa Rome Welcome to the Aphasia Access Aphasia Conversations Podcast. I'm Lyssa Rome. I'm a speech language pathologist on staff at the Aphasia Center of California and I see clients with aphasia and other neurogenic communication disorders in my LPAA-focused private practice. I'm also a member of the Aphasia Access Podcast Working Group. Aphasia Access strives to provide members with information, inspiration and ideas that support their aphasia care through a variety of educational materials and resources.   I'm today's host for an episode that will feature Dr. Elizabeth Hoover, who was selected as a 2024 Tavistock Trust for Aphasia Distinguished Scholar, USA and Canada.   Liz Hoover is a clinical professor of speech language and hearing sciences and the clinical director of the Aphasia Resource Center at Boston University. She holds board certification from the Academy of Neurologic Communication Disorders and Sciences, or ANCDS, and is an ASHA fellow. Liz was a founding member of Aphasia Access and served on the board for several years. She has 30 years of experience working with people with aphasia and other communication disorders across the continuum of care. She's contributed to numerous presentations and publications, and most of her work focuses on the effectiveness of group treatment for individuals with aphasia. Liz, welcome back to the podcast.   So in 2017 you spoke with Ellen Bernstein Ellis about intensive comprehensive aphasia programs or ICAPs and inter professional practice at the Aphasia Resource Center at BU and treatment for verb production using VNest, among other topics. So this time, I thought we could focus on some of your recent research with Gayle DeDe and others on conversation group treatment.   Liz Hoover Sounds good.   Lyssa Rome All right, so my first question is how you became interested in studying group treatment?   Liz Hoover Yeah, I actually have Dr. Jan Avent to thank for my interest in groups. She was my aphasia professor when I was a graduate student doing my masters at Cal State East Bay. As you know, Cal State East Bay is home to the Aphasia Treatment Program. When I was there, it preceded ATP. But I was involved in her cooperative group treatment study, and as a graduate student, I was allowed to facilitate some of her groups in this study, and I was involved in the moderate-to-severe group. She was also incredibly generous at sharing that very early body of work for socially oriented group treatments and exposing us to the work of John Lyons and Audrey Holland. Jan also invited us to go to a conference on group treatment that was run by the Life Link group. It's out of Texas Woman's University, Delaina Walker-Batson and Jean Ford. And it just was a life changing and pivotal experience for me in recognizing how group treatment could not be just an adjunct to individual goals, but actually be the type of treatment that is beneficial for folks with aphasia. So it's been a love my entire career.   Lyssa Rome And now I know you've been studying group treatment in this randomized control trial. This was a collaborative research project, so I'm hoping you can tell us a little bit more about that project. What were your research questions? Tell us a little bit more.   Liz Hoover Yeah, so thank you. I'll just start by acknowledging that the work is funded by two NIDCD grants, and to acknowledge their generosity, and then also acknowledge Dr. Gayle DeDe, who is currently at Temple University. She is a co- main PI in this work, and of course it wouldn't have happened without her. So you know, Gayle and I have known each other for many, many years. She's a former student, doctoral student at Boston University, and by way of background, she and I were interested in working together and interested in trying to build on some evidence for group treatment. I think we drank the Kool Aid early on, as you might say.   And you know, just looking at the literature, there have been two trials on the evidence for this kind of work. And so those of us who are involved in groups, know that it's helpful for people with aphasia, our clients tell us how much they enjoy it, and they vote with their feet, right? In that they come back for more treatments. And aphasia centers have grown dramatically in the last couple of decades in the United States.   So clearly we know they work, but what we don't know is why they work. What are those essential ingredients, and how is that driving the change that we think we see? And from a personal perspective, that's important for me to understand and for us to have explained in the literature, because until we can justify it in the scientific terms, I worry it will forever be a private-pay adjunct that is only accessible to people who can pay for it, or who are lucky enough to be close enough to a center that can get them access—virtual groups aside, and the advent of that—but it's important that I think this intervention is validated to the scientific community in our field.   So we designed this trial. It's a randomized control trial to help build the research evidence for conversation, group treatment, and to also look at the critical components. This was inspired by a paper actually from Nina Simmons Mackie in 2014 and Linda Worrell. They looked at group treatment and showed that there were at least eight first-tier elements that changed the variability or on which we might modify group conversation treatment. And so, you know, if we're all doing things differently, how can we predict the change, and how can we expect outcomes?   Lyssa Rome So I was hoping you could describe this randomized, controlled trial. You know, it was collaborative, and I'm curious about what you and your collaborators had as your research questions.   Liz Hoover So our primary aims of the study were to understand if communication or conversation treatment is associated with changes in measures of communicative ability and psychosocial measures. So that's a general effectiveness question. And then to look in more deeply to see if the group size or the group composition or even the individual profile of the client with aphasia influences the expected outcome.   Because if you think about group treatment, the size of the group is not an insignificant issue, right? So a small group environment of two people has much more… it still gives you some peer support from the other individual with aphasia, but you have many opportunities for conversational turns and linguistic and communication practice and to drive the saliency of the conversation in a direction that's meaningful and useful and informative.   Whereas in a large group environment of say, six to eight people with aphasia and two clinicians, you might see much more influence in the needed social support and vicarious learning and shared lived experience and so forth, and still have some opportunity for communication and linguistic practice. So there's conflicting hypotheses there about which group environment might be better for one individual over another.   And then there's the question of, well, who's in that group with you? Does that matter? Some of the literature says that if you have somebody with a different profile of aphasia, it can set up a therapeutic benefit of the helper experience, where you can gain purpose by enabling and supporting and being a facilitator of somebody else with aphasia.   But if you're in a group environment where your peers have similar conversation goals as you, maybe your practice turns, and your ability to learn vicariously from their conversation turns is greater. So again, two conflicting theories here about what might be best. So we decided to try and manipulate these group environments and measure outcomes on several different communication measures. We selected measures that were linguistic, functional, and psychosocial.   We collected data over four years. The first two years, we enrolled people with all different kinds of profiles of aphasia. The only inclusion criteria from a communication perspective, as you needed some ability to comprehend at a sentence level, so that you could process what was being said by the other people in the group. And in year one, the treatment was at Boston University and Temple University, which is where Gayle's aphasia center is housed. In year two, we added a community site at the Adler Aphasia Center and Maywood, New Jersey, so we had three sites going.   The treatment conditions were dyad, large group, and then a no treatment group. So this group was tested at the same time, didn't get any other intervention, and then we gave them group treatment once the testing cycle was over. So we call that a historical control or a delayed-treatment control group. And then in years three and four, we aim to enroll people who had homogeneous profiles.   So the first through the third cycle was people with moderate to severe profiles. And then in the final, fourth cycle, it was people with mild profiles with aphasia. This allowed us to collect enough data in enough size to be able to look at overall effectiveness and then effects of heterogeneity or homogeneity in the group, and the influence of the profile of aphasia, as well as the group size.   And across the four years, we aim to enroll 216 participants, and 193 completed the study. So it's the largest of its kind for this particular kind of group treatment that we know of anyway. So this data set has allowed us to look at overall efficacy of conversation group treatment, and then also take a look at a couple of those critical ingredients. Does the size of the group make a difference? And does the composition of your group make a difference?   Lyssa Rome And what did you find?   Liz Hoover Well, we're not quite done with all of our analysis yet, but we found overall that there's a significant treatment effect for just the treatment conditions, not the control group. So whether you were in the dyad or whether you were in a large treatment group, you got better on some of the outcome measures we selected. And the control group not only didn't but on a couple of those measures, their performance actually declined. And so showing significantly that there's a treatment effect. Did you have a question?   Lyssa Rome Yeah, I wanted to interrupt and ask, what were the outcome measures? What outcome measures were you looking at?   Liz Hoover Yeah. So we had about 14 measures in total that aligned with the core outcome set that was established by the ROMA group. So we had as our linguistic measure the Comprehensive Aphasia Test. We had a primary outcome measure, which was a patient reported measure of functional communication, which is the ACOM by Will Hula and colleagues, the Aphasia Communication Outcome measure, we had Audrey Holland and colleagues' objective functional measure, the CADL, and then a series of other psychosocial and patient reported outcome measures, so the wall question from the ALA, the Moss Social Scale, the Communication Confidence Rating Scale in Aphasia by Leora Cherney and Edie Babbitt.   Lyssa Rome Thank you. When I interrupted you to ask about outcome measures. You were telling us about some of the findings so far.   Liz Hoover Yeah, so our primary outcome measures showed significant changes in language for both the treatment conditions and a slightly larger effect for the large group. And then we saw, at a more micro level, the results pointing to a complex interaction, actually, between the group size and the treatment outcome. So we saw changes on more linguistic measures. like the repetition sub scores of the CAT and verb naming from another naming subtest for the dyad group, whereas bigger, more robust changes on the ACOM the CADL and the discourse measure from the CAT for the large group.   And then diving in a little bit more deeply for the composition, these data are actually quite interesting. The papers are in review and preparation at the moment, but it looks like we are seeing significant changes for the moderate-to-severe group on objective functional measures and patient reported functional measures of communication, which is so exciting to see for this particular cohort, whose naming scores were zero, in some cases, on entrance, and we're seeing for the mild group, some changes on auditory comprehension, naming, not surprisingly, and also the ACOM and the CADL. So they're showing the same changes, just with different effect sizes or slightly different ranges. And once again, no change in the control group, and in some cases, on some measures, we're seeing a decline in performance over time.   So it's validating that the intervention is helpful in general. What we found with the homogeneous groups is that in a homogeneous large group environment, those groups seem to do a little better. There's a significant effect over time between the homogeneous and the heterogeneous groups. So thinking about why that might have taken place, we wonder if the shared lived experience of your profile of aphasia, your focus on similar kinds of communication, or linguistic targets within the conversation environment might be helping to offset the limited number of practice trials you get in that larger group environment.   So that's an interesting finding to see these differences in who's in the group with you. Because I think clinically, we tend to assign groups, or sort of schedule groups according to what's convenient for the client, what might be pragmatic for the setting, without really wondering why one group could be important or one group might be preferential. If we think about it, there are conflicting hypotheses as to why a group of your like aphasia severity might have a different outcome, right? That idea that you can help people who have a different profile than you, that you're sharing different kinds of models of communication, versus that perhaps more intense practice effect when you share more specific goals and targets and lived experiences. So it's interesting to think about the group environment from that perspective, I think,   Lyssa Rome And to have also some evidence that clinicians and people at aphasia centers can look to help make decisions about group compositions, I think is incredibly helpful.   Earlier, you mentioned that one of the goals of this research project has been to identify the active ingredients of group therapy. And I know that you've been part of a working group for the Rehabilitation Treatment Specification System, or RTSS. Applying that, how have you tried to identify the active ingredients and what? What do you think it is about these treatments that actually drives change?   Liz Hoover I'll first of all say, this is a work in process. You know, I don't think we've got all of the answers. We're just starting to think about it with the idea, again, that if we clinically decide to make some changes to our group, we're at least doing it with some information behind us, and it's a thoughtful and intentional change, as opposed to a gut reaction or a happenstance change. So Gayle and I have worked on developing this image, or this model. It's in a couple of our papers. We can share the resources for that. But it's about trying to think of the flow of communication, group treatment, and what aspects of the treatment might be influential in the outcomes we see downstream.   I think for group treatment, you can't separate entirely many of the ingredients. Group treatment is multifaceted, it's interconnected, and it's not possible—I would heavily debate that with anybody—I don't think it's possible to sort of truly separate some of these ingredients. But when you alter the composition or the environment in which you do the treatment, I do think we are influencing the relative weight of these ingredients.   So we've been thinking about there being this group dynamics component, which is the supportive environment of the peers in the group with you, that social support, the insider affiliation and shared lived experience, the opportunity to observe and see the success of some of these different communication strategies, so that vicarious learning that takes place as you see somebody else practice. But also, I think, cope in a trajectory of your treatment process.   And then we've got linguistic practice so that turn taking where you're actually trying to communicate verbally using supported communication where you're expanding on your utterances or trying to communicate verbally in a specific way or process particular kinds of linguistic targets. A then communication practice in terms of that multimodal effectiveness of communication.   And these then are linked to these three ingredients, dynamic group dynamics, linguistic practice and communication practice. They each have their own mechanism of action or a treatment theory that explains how they might affect change. So for linguistic practice, it's the amount of practice, but also how you hear it practiced or see it practiced with the other group participant. And the same thing for the various multimodal communication acts. And in thinking about a large group versus the dyad or a small group, you know you've got this conflicting hypothesis or the setup for a competing best group, or benefit in that the large group will influence more broadly in the group dynamics, or more deeply in the group dynamics, in that there's a much bigger opportunity to see the vicarious learning and experience the support and potentially experience the communication practice, given a varied number of participants.   But yet in the dyad, your opportunity for linguistic practice is much, much stronger. And our work has counted this the exponential number of turns you get in a dyad versus a large group. And you know, I think that's why the results we saw with the dyad on those linguistic outcomes were unique to that group environment.   Lyssa Rome It points, I think, to the complexity of decision making around group structure and what's right for which client, maybe even so it sounds like some of that work is still in progress. I'm curious about sort of thinking about what you know so far based on this work, what advice would you have for clinicians who are working in aphasia centers or or helping to sort of think about the structure of group treatments? What should clinicians in those roles keep in mind?   Liz Hoover Yeah, that's a great question, and I'll add the caveat that this may change. My advice for this may change in a year's time, or it might evolve as we learn more. But I think what it means is that the decisions you make should be thoughtful. We're starting to learn more about severity in aphasia and how that influences the outcomes. So I think, what is it that your client wants to get out of the group? If they're interested in more linguistic changes, then perhaps the dyad is a better place to start. If they clearly need, or are voicing the need, for more psychosocial support, then the large, you know, traditional sized and perhaps a homogeneous group is the right place to start. But they're both more effective than no treatment. And so being, there's no wrong answer. It's just understanding your client's needs. Is there a better fit?   And I think that's, that's, that's my wish, that people don't see conversation as something that you do at the beginning to build a rapport, but that it's worthy of being an intervention target. It should be most people's primary goal. I think, right, when we ask, what is it you'd like? “I want to talk more. I want to have a conversation.” Audrey Holland would say it's a moral imperative to to treat the conversation and to listen to folks' stories. So just to think carefully about what it is your client wants to achieve, and if there's an environment in which that might be easier to help them achieve that.   Lyssa Rome It's interesting, as you were saying that I was thinking about what you said earlier on about sort of convincing funders about the value of group treatment, but what you're saying now makes me think that it's all your work is also valuable in convincing speech therapists that referrals to groups or dyads is valuable and and also for people with aphasia and their families that it's worth seeking out.   I'm curious about where in the continuum of care this started for the people who were in your trial. I mean, were these people with chronic aphasia who had had strokes years earlier? Was it a mix? And did that make a difference?   Liz Hoover It was a mix. I think our earliest participant was six months post-onset. Our most chronic participant was 26 years post-onset. So a wide range. We want, obviously, from a study perspective, we needed folks to be outside of the traditional window of spontaneous recovery in stroke-induced aphasia.   But it was important to us to have a treatment dose that was reasonable and applicable to a United States healthcare climate, right? So twice a week for an hour is something that people would get reimbursed for. The overall dose is the minimum that's been shown to be effective in the RELEASE collaborative trial papers. And then, you know, but still, half, less than half the dose that the Elman and Bernstein Ellis study found to be effective. So there may be some wiggle room there to see if, if a larger dose is more effective.   But yeah, I think it's that idea of finding funding, convincing people that this is not just a reasonable treatment approach, but a good approach for many outcomes for people with chronic aphasia. I mean, you know, one of the biggest criticisms we hear from the giants in our field is the frustration with aphasia being treated like it's a quick fix and can be done. But you know, so much of the work shows that people are only just beginning to understand their condition by the time they're discharged from traditional outpatient services. And so there's a need for ongoing treatment indefinitely, I think, as your goals change, as you age, and as your wish to participate in different things changes over a lifetime,   Lyssa Rome Yeah, absolutely. And I think too, when we think about sort of the role of hope, if you know, if there is additional evidence showing that there can be change after that sort of traditional initial period, when we think that change happens the most, that can provide a lot of hope and motivation, I think, to people.   Liz Hoover yeah, we're look going to be looking next at predictors of change, so looking at our study entrance scores and trying to identify which participants were the responders versus the non-responders that you know, because group effects are one thing, but it's good to see who seems to benefit the most from these individual types of environments.   And an early finding is that confidence, or what some people in the field, I'm learning now are referring to as actually communication self-efficacy, but that previous exposure to group potentially and that confidence in your communication is inversely correlated with benefits from treatment on other measures. So if you've got a low confidence in your ability to communicate functionally in different environments, you're predicted to be a responder to conversation treatment.   Lyssa Rome Oh, that's really interesting. What else are you looking forward to working on when it comes to this data set or other projects that you have going on?   Liz Hoover Yeah. So as I mentioned, there's a lot of data still for us to dig into, looking at those individual responders or which factors or variables might make an impact. There is the very next on the list, we're also going to be looking very shortly at the dialogic conversation outcomes. So, it's a conversation treatment. How has conversation changed? That's a question we need to answer. So we're looking at that currently, and might look more closely at other measures. And then I think the question of the dose is an interesting one. The question of how individual variables or the saliency of the group may impact change is another potentially interesting question. There are many different directions you can go.   You know, we've got 193 participants in the study, with three separate testing time points, so it's a lot of data to look at still. And I think we want to be sure we understand what we're looking at, and what those active ingredients might be, that we've got the constructs well defined before we start to recruit for another study and to expand on these findings further.   Lyssa Rome When we were meeting earlier, getting ready for this talk, you mentioned to me a really valuable video resource, and I wanted to make sure we take some time to highlight that. Can you tell us a little bit about what you worked on with your colleagues at Boston University?   Liz Hoover Yes, thank you. So I'll tell you a little bit. We have a video education series. Some of you may have heard about this already, but it's up on our website so bu.edu/aphasiacenter, and we'll still share that link as well. And it's a series of short, aphasia-friendly videos that are curated by our community to give advice and share lived experiences from people with aphasia and their care partners.   This project came about right on the heels of the COVID shutdown at our university. I am involved in our diagnostic clinic, and I was seeing folks who had been in acute care through COVID being treated with people who were wearing masks, who had incredibly shortened lengths of stay because people you know rightly, were trying to get them out of a potentially vulnerable environment. And what we were seeing is a newly diagnosed cohort of people with aphasia who were so under-informed about their condition, and Nina that has a famous quote right of the public being woefully uninformed of the aphasia condition and you don't think it can get any worse until It does.   And I thought, gosh, wouldn't it be wonderful to be able to point them to some short education videos that are by people who have lived their same journey or a version of their same journey. So we fundraised and collaborated with a local production company to come up with these videos. And I'll share, Lyssa, we just learned last week that this video series has been awarded the ASHA 2025 Media Outreach Award. So it's an award winning series.   Lyssa Rome Yeah, that's fantastic, and it's so well deserved. They're really beautifully and professionally produced. And I think I really appreciated hearing from so many different people with aphasia about their experiences as the condition is sort of explained more. So thank you for sharing those and we'll put the links in our show notes along with links to the other articles that you've mentioned in this conversation in our show notes. So thanks.   Liz Hoover Yeah, and I'll just put a big shout out to my colleague, Jerry Kaplan, who's the amazing interviewer and facilitator in many of these videos, and the production company, which is Midnight Brunch. But again, the cinematography and the lighting. They're beautifully done. I think I'm very, very happy with them.   Lyssa Rome Yeah, congrats again on the award too. So to wrap up, I'm wondering if there's anything else that you want listeners to take away from this conversation or from the work that you've been doing on conversation treatments.   Liz Hoover I would just say that I would encourage everybody to try group treatment. It's a wonderful option for intervention for people, and to remind everyone of Barbara Shadden and Katie Strong's work, of that embedded storytelling that can come out in conversation, and of the wonderful Audrey Holland's words, of it being a moral imperative to help people tell their story and to converse. It's yeah… You'll drink the Kool Aid if you try it. Let me just put it that way. It's a wonderful intervention that seems to be meaningful for most clients I've ever had the privilege to work with.   Lyssa Rome I agree with that. And meaningful too, I think for clinicians who get to do the work.   Liz Hoover, thank you so much for your work and for coming to talk with us again, for making your second appearance on the podcast. It's been great talking with you.   Liz Hoover Thank you. It's been fun. I appreciate it.   Lyssa Rome And thanks also to our listeners for the references and resources mentioned in today's show. Please see our show notes. They're available on our website, www.aphasiaaccess.org. There, you can also become a member of our organization, browse our growing library of materials and find out about the Aphasia Access Academy. If you have an idea for a future podcast episode, email us at info@aphasia access.org.   Thanks again for your ongoing support of Aphasia Access. For Aphasia Access Conversations. I'm Lyssa Rome.       Resources Walker-Batson, D., Curtis, S., Smith, P., & Ford, J. (1999). An alternative model for the treatment of aphasia: The Lifelink© approach. In R. Elman (Ed.), Group treatment for neurogenic communication disorders: The expert clinician's approach (pp. 67-75). Woburn, MA: Butterworth-Heinemann   Hoover, E.L., DeDe, G., Maas, E. (2021). A randomized controlled trial of the effects of group conversation treatment on monologic discourse in aphasia. Journal of Speech-Language and Hearing Research doi/10.1044/2021_JSLHR-21-00023 Hoover, E., Szabo, G., Kohen, F., Vitale, S., McCloskey, N., Maas, E., Kularni, V., & DeDe., G. (2025). The benefits of conversation group treatment for individuals with chronic aphasia: Updated evidence from a multisite randomized controlled trial on measures of language and communication. American Journal of Speech Language Pathology. DOI: 10.1044/2025_AJSLP-24-00279   Aphasia Resource Center at BU   Living with Aphasia video series Aphasia Access Podcast Episode #15: In Conversation with Liz Hoover

Aging-US
Gut Microbiome Influences Proteins That Drive Aging and Disease

Aging-US

Play Episode Listen Later Sep 9, 2025 4:21


BUFFALO, NY — September 9, 2025 — A new #research paper was #published in Volume 17, Issue 8 of Aging-US on August 1, 2025, titled “Causal relationships between gut microbiome and hundreds of age-related traits: evidence of a replicable effect on ApoM protein levels.” In this study, Federica Grosso, Daniela Zanetti, and Serena Sanna from the Institute for Genetic and Biomedical Research (IRGB) of the National Research Council (CNR), Italy, uncovered new associations between gut microbiome and the aging process. The researchers found that certain microbial characteristics may causally influence proteins in the blood linked to inflammation and heart health. These findings could help explain how age-related diseases like cardiovascular conditions and macular degeneration are influenced by changes in the gut ecosystem. The gut microbiome, the collection of microorganisms living in the digestive system, plays a major role in immune function and metabolic health. As people age, this microbial community shifts, often leading to imbalances associated with inflammation and chronic disease. To explore how these changes might affect the body, the researchers used Mendelian Randomization—a method that leverages genetic data—to test over 55,000 possible causal connections between gut microbial characteristics and age-related health indicators. The study identified 91 significant causal relationships. Among them, the researchers found that higher levels of certain gut bacteria were associated with increased risk of age-related macular degeneration. Another finding was the association between a metabolic pathway in the gut, called “purine nucleotides degradation II,” and lower levels of apolipoprotein M (ApoM), a protein that helps protect against heart disease. This result was validated using data from an independent study, strengthening the evidence. “Unlike previous studies, we performed replication analyses for the significant results using independent GWAS datasets, a fundamental step that has often been overlooked.” The study also revealed how some bacteria may affect protein levels differently depending on a person's blood type. Specifically, in individuals with blood type A, certain gut microbes that can break down a sugar called GalNAc may influence proteins related to inflammation and cardiovascular health. This suggests that personalized approaches to managing age-related diseases could consider both gut microbiota and genetic factors like blood type. The research team followed strict guidelines to reduce false findings and confirmed its key results in independent datasets. By carefully testing for reverse causality and other biases, the authors provided strong evidence that the gut microbiome can influence critical aspects of aging biology. Although more research is needed to fully understand the biological pathways involved, these findings suggest that targeting the gut microbiota might help delay or reduce age-related inflammation and disease. The study lays a foundation for future therapeutic strategies that could include diet, probiotics, or other microbiome-based interventions. DOI - https://doi.org/10.18632/aging.206293 Corresponding author - Serena Sanna - serena.sanna@cnr.it Abstract video - https://www.youtube.com/watch?v=CWky6jlHKUs Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Let's Talk Creation
Episode 119: Creationist Plate Tectonics??? With Sarah Peterson

Let's Talk Creation

Play Episode Listen Later Sep 8, 2025 53:45


Plate tectonics tells us all about how the continents are drifting along at a centimeter or two a year, ever so gradually reshaping the surface of the earth, remaking the ocean floor, and causing earthquakes and volcanoes the world over. But what if it went a lot faster? In this episode, Todd and Paul chat with geophysicist Sarah Peterson about the CATASTROPHIC version of plate tectonics that has become the leading model of how the Flood happened. Sarah walks us through both the basic concepts of tectonics and how Catastrophic Plate Tectonics explains even more than the slow, conventional version. If you've ever wondered how volcanoes, earthquakes, and continental drift fit in the creation model, this episode is for you!Papers mentioned in this episodePetersen, Sarah and Baumgardner, John (2023) "Catastrophic Plate Tectonics and the Tectonics of Western North America," Proceedings of the International Conference on Creationism: Vol. 9, Article 33.DOI: 10.15385/jpicc.2023.9.1.54Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol9/iss1/33Austin, Steven A.; Baumgardner, John R.; Humphreys, D. Russell; Snelling, Andrew A.; Vardiman, Larry; and Wise, Kurt P. (1994) "Catastrophic Plate Tectonics: A Global Flood Model of Earth History," Proceedings of the International Conference on Creationism: Vol. 3, Article 56.Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol3/iss1/56Baumgardner, John R. (1994) "Computer Modeling of the Large Scale Tectonics Associated With the Genesis Flood," Proceedings of the International Conference on Creationism: Vol. 3, Article 15.Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol3/iss1/15Baumgardner, John R. (1994) "Runaway Subduction as the Driving Mechanism for the Genesis Flood," Proceedings of the International Conference on Creationism: Vol. 3, Article 14.Available at: https://digitalcommons.cedarville.edu/icc_proceedings/vol3/iss1/14

Fully Functional Parents
Killing Bunnies for Dinner! And Fighting Over Shotgun!

Fully Functional Parents

Play Episode Listen Later Sep 7, 2025 12:32


A rerun!! Doi!! Cause I've known Emilie for years now!!

Communicable
Communicable E35: From Ebola to COVID-19 — Graham and Kobinger on building vaccines

Communicable

Play Episode Listen Later Sep 7, 2025 58:13


In this episode of Communicable, Angela Huttner and Erin McCreary invite two titans of vaccinology, Barney Graham (Atlanta, USA), former deputy director of the NIH NIAID Vaccine Research Center and architect of the mRNA vaccines against COVID-19, and Gary Kobinger (Galveston, USA), leading virologist in the development of the first effective Ebola vaccine, rVSV-ZEBOV, for a candid conversation about their direct experience building two of the most well known vaccines to date, and deploying them to the public. The episode also reviews the different vaccine platforms and addresses vaccine hesitancy, equitable access to vaccines, and global health equity. This episode was edited by Kathryn Hostettler and peer reviewed by Eren Ozturk of Ankara University, Ankara, Türkiye.  Terms and sourcesVSV, vesicular stomatitis virusZEBOV, Zaire Ebolavirus rVSV-ZEBOV, recombinant vesicular stomatitis virus expressing the (Zaire) Ebolavirus glycoprotein (vaccine)VRC, the NIH Vaccine Research Center of NIAID Morehouse School of Medicine Satcher Global Health Equity InstituteGuardRX, https://www.guardrx.org/en/who-we-are/ ReferencesMarzi A, et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science 2015. DOI: 10.1126/science.aab3920 Agnandji S, Huttner A, Zinser M, et al. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. New Engl J Med 2015. DOI: 10.1056/NEJMoa1502924Graham BS and Corbett KS. Prototype pathogen approach for pandemic preparedness: world on fire. J Clin Invest 2020. DOI: 10.1172/JCI139601Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. New Engl J Med 2020. DOI: 10.1056/NEJMoa2022483

Dr. Chapa’s Clinical Pearls.
Eric's Encounters: Suppl. to Our Prior Episode

Dr. Chapa’s Clinical Pearls.

Play Episode Listen Later Sep 6, 2025 8:51


We have a wonderful podacst community! Within 24 hours of our immediate past episode release, one close friend- and fellow OBGYN, Dr. Eric Colton (OB Hospitalist Group) reached out and shared valuable words of wisdom regarding a potentially deadly complication of the CS-scar defect...the CS scar ectopic pregnancy. Listen in for Dr. Colton's cameo and details. 1. Ban, Yanli MD, PhD; Shen, Jia MD; Wang, Xia MD; Zhang, Teng MD, PhD; Lu, Xuxu MD; Qu, Wenjie MD; Hao, Yiping MD; Mao, Zhonghao MD; Li, Shizhen MD; Tao, Guowei MD, PhD; Wang, Fang MD, PhD; Zhao, Ying MD, PhD; Zhang, Xiaolei MD, PhD; Zhang, Yuan MD, PhD; Zhang, Guiyu MD, PhD; Cui, Baoxia MD, PhD. Cesarean Scar Ectopic Pregnancy Clinical Classification System With Recommended Surgical Strategy. Obstetrics & Gynecology 141(5):p 927-936, May 2023. | DOI: 10.1097/AOG.0000000000005113

Herpetological Highlights
234 Hot Dragons, Cold Dragons

Herpetological Highlights

Play Episode Listen Later Sep 5, 2025 46:43


We recap some of our recent travels, and then chat about bearded dragons. A new study shows that these lizards are making decisions about how they maintain their body temperature, and this has a knock-on effect on how well they perform during their daily lives. Being cold-blooded is complicated. Become a Patreon: https://www.patreon.com/herphighlights Merch: https://www.redbubble.com/people/herphighlights/shop Full reference list available here: http://www.herphighlights.podbean.com Main Paper References: Wild KH, Roe JH, Curran J, Pearson PR, Schwanz L, Georges A, Sarre SD. 2025. Thermal performance curves, activity and survival in a free‐ranging ectotherm. Journal of Animal Ecology. DOI: 10.1111/1365-2656.70091. Species of the Bi-Week: Petzold A, Glaw F, Mullin KE, Rakotoarison A, Raselimanana AP, Cottini A, Orozco-terWengel P, Kohler J, Protzel D, Vences M, Hofreiter M, Scherz MD. 2025. A preliminary assessment of the diversity in the frog genus Anilany (Microhylidae: Cophylinae) with description of a new species from western Madagascar. Salamandra. Other Mentioned Papers/Studies: Marshall BM, Strine CT, Gore ML, Eskew EA, Stringham OC, Cardoso P, Chekunov S, Watters F, Fukushima C, García-Díaz P, Sinclair JS, Tlusty MF, Almeida RJ, Valdez JW, Hughes AC. 2025. Mapping the global dimensions of US wildlife imports. Current Biology:S0960982225008784. DOI: 10.1016/j.cub.2025.07.012. Editing and Music: Intro/outro – Treehouse by Ed Nelson Species Bi-week theme – Michael Timothy Other Music – The Passion HiFi, https://www.thepassionhifi.com

Manx Radio's Mannin Line
It's Mannin Line with Andy Wint - Friday 5th September 2025

Manx Radio's Mannin Line

Play Episode Listen Later Sep 5, 2025 50:45


The role of sports clubs in children's lives, DOI or local authority cutting the vegetation back, the vandalism at Cornaa & the future for Net Zero policies. It's Mannin Line with Andy Wint - Friday 5th September 2025

Deconstructing Disney

Episode SummaryErin and Rachel wallow through an elderly man's grief journey with Pixar's critically acclaimed Up (2009). They argue the beautiful art and cute sidekicks aren't enough to redeem this (admittedly beloved) film, especially since the (admittedly moving) love story invokes the classic “dead wife” trope. We'll keep sailing our balloon house onto the next one, please and thank you. Episode BibliographyAdler, S. (2008, August 7). 'Up' And Coming: 3-D Pixar Movie Tells A 'Coming Of Old Age' Story, Director Says. MTV. https://web.archive.org/web/20100318060539/http://www.mtv.com/movies/news/articles/1592302/story.jhtmlThe Associated Press. (2009, May 12). Q&A: Pete Docter. The Hollywood Reporter. https://www.hollywoodreporter.com/business/business-news/qampa-pete-docter-83783/Berardinelli, J. (2009, May 26). Up (United States, 2009). ReelViews. https://www.reelviews.net/reelviews/upBlock, A. B. (2009, November 17). Anatomy of a Contender: ‘Up'. The Hollywood Reporter. https://www.hollywoodreporter.com/business/business-news/anatomy-contender-91440/Brooks, X. (2009, March 19). Curtain will go Up on this year's Cannes with 3-D yarn | Cannes 2009. The Guardian. https://www.theguardian.com/film/2009/mar/19/up-first-animation-to-open-cannes-film-festivalChen, D. (2009, May 28). Marketing Up's Asian-American Lead Character. SlashFilm. https://www.slashfilm.com/503927/marketing-ups-asian-american-lead-character/Coconut Press. (2023, August 16). The Making of Up: Pixar Travels to Venezuela 4k. YouTube. https://www.youtube.com/watch?v=jXCHlcrMgLYCorliss, R. (2009, May 7). Going Up. TIME. https://web.archive.org/web/20090513203932/http://www.time.com/time/arts/article/0,8599,1896685-1,00.htmlCorliss, R. (2009, May 28). Up, Up and Away: Another New High for Pixar. Time Magazine. https://time.com/archive/6688401/up-up-and-away-another-new-high-for-pixar/Docter, P. (Director). (2009). Up [Film]. Pixar Animation Studios.DVDFilmBonus. (2023, July 16). Up 2009 ( Pixar ) Making of & Behind the Scenes. YouTube. https://www.youtube.com/watch?v=hPQuzPm73foErikson E.H., & Erikson, J.M. (1982). Life cycle completed. W.W. Norton & CompanyFreer, I. (2009, October 3). Up. Empire Online. https://www.empireonline.com/movies/reviews/movie-2-review/Hartlaub, P. (2009, May 27). Oakland's Fentons Creamery in Pixar film 'Up'. SFGate. https://www.sfgate.com/entertainment/article/Oakland-s-Fentons-Creamery-in-Pixar-film-Up-3297072.phpHauser, T. (2016). The Art of Up. Chronicle Books LLC.Hogan, R. (2009, June 1). Pixar's Up review. Den of Geek. https://www.denofgeek.com/movies/pixars-up-review-2/Horn, J. (2009, May 10). up, up and away. Los Angeles Times. https://www.latimes.com/archives/la-xpm-2009-may-10-ca-up10-story.htmlHornaday, A. (2009, May 29). Up. The Washington Post. https://web.archive.org/web/20091027073954/http://www.washingtonpost.com/gog/movies/up,1156226.htmlKhoo, I. (2015, July 13). Pregnancy Loss: The Surprising Movie That Understands Miscarriage. HuffPost Canada. https://www.huffpost.com/archive/ca/entry/pregnancy-loss-the-surprising-movie-that-understands-miscarriag_n_7786224King, S. (2009, May 28). Jordan Nagai, 'Up'. Los Angeles Times. https://web.archive.org/web/20121106123435/http://articles.latimes.com/2009/may/28/entertainment/et-jordanpete28The Korean Face of Pixar's Latest Star. (2009, June 3). The Chosun Daily. https://www.chosun.com/english/people-en/2009/06/03/NXQOOEMZNUTRQNAZ7NTDTTGBUU/Ksieh, K. (2009, May 29). Jordan Nagai as Russell in UP. Channel APA. https://web.archive.org/web/20121110102130/http://www.channelapa.com/2009/05/jordan-nagai-as-russell-in-up.htmlMedia Action Network for Asian Americans. (2009, September 2). ASIAN AMERICAN MEDIA WATCHDOG GROUP PRAISES DISNEY/PIXAR'S "UP" FOR CREATING ASIAN AMERICAN PROTAGONIST. MANAA. https://web.archive.org/web/20090902105114/http://www.manaa.org/up_press_release.htmlMeinel, D. (2014). Empire is out there!?: The spirit of imperialism in the Pixar animated film ‘Up'. Traces. NECSUS. https://necsus-ejms.org/empire-spirit-imperialism-pixar-animated-film/#_edn12Meinel, D. (2016). Pixar's America. Palgrave MacMillan. DOI: 10.1007/978-3-319-31634-5_7Morgenstern, J. (2009, May 14). Reaching for the Sky, 'Up' Fails to Soar - WSJ. The Wall Street Journal. https://www.wsj.com/articles/SB124226358415817813Piane, C. (2010, April 9). EWP Honors Pixar Films And Jordan Nagai At 44th Anniversary Visionary Awards 4/19. Broadway World. https://www.broadwayworld.com/los-angeles/article/EWP-Honors-Pixar-Films-And-Jordan-Nagai-At-44th-Anniversary-Visionary-Awards-419-20100409Press Release. (2009, November 8). Interview: Pete Doctor on Disney/Pixar's UP. Major Spoilers. https://web.archive.org/web/20100208140509/http://www.majorspoilers.com/archives/27376.htm/Rechtshaffen, M. (2009, May 12). Up - Film Review. The Hollywood Reporter. https://web.archive.org/web/20120315171219/http://www1.hollywoodreporter.com/hr/film-reviews/up-film-review-1003972156.storySchilling, V. (2019, September 15). Boy Scouts ‘have been one of the worst culprits' of cultural appropriation. ICT. https://ictnews.org/news/boy-scouts-have-been-one-of-the-worst-culprits-of-cultural-appropriation/Tell Me More Staff. (2013, September 9). Angry Asian Man Not So Angry : Code Switch. NPR. https://www.npr.org/sections/codeswitch/2013/09/09/219725276/angry-asian-man-not-so-angryUp (2009 film). (n.d.). Wikipedia. https://en.wikipedia.org/wiki/Up_(2009_film)Wooden, S.R., & Gillam, K. (2014). Pixar's boy stories: Masculinity in a postmodern age. Rowman & Littlefield Publishers. Young, S. (2020, January 16). Exploring the dead wives in family movies trope. Nerdist. https://nerdist.com/article/dead-wives-family-movies-dolittle/Zacharek, S. (2009, May 29). Up. Salon. https://www.salon.com/2009/05/29/up_review/

Aging-US
Idiopathic Pulmonary Fibrosis Identified as a Model for Anti-Aging Drug Development

Aging-US

Play Episode Listen Later Sep 4, 2025 4:21


BUFFALO, NY — September 4, 2025 — A new #research perspective was #published in Volume 17, Issue 8 of Aging (Aging-US) on August 16, 2025, titled “Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis.” In this research perspective, Alex Zhavoronkov, Dominika Wilczok, Feng Ren, and Fedor Galkin, from Insilico Medicine, Buck Institute for Research on Aging, and Duke University, propose a new method to evaluate age-related diseases based on how closely they align with the biological processes of aging. Their analysis shows that idiopathic pulmonary fibrosis (IPF), a progressive lung condition, is one of the diseases most strongly associated with aging. This makes IPF a promising model for testing new anti-aging therapies with the potential to treat multiple age-related conditions. “This perspective explores how aging-related diseases (ARDs) can serve as experimental platforms for discovering new geroprotective interventions.” While many age-related diseases are used as models for aging research, not all accurately reflect the biology of aging. To address this, the authors developed a scoring system that measures how closely a disease is connected to the key hallmarks of aging, such as inflammation, genetic instability, and impaired cellular repair. Using this system, they evaluated 13 common age-related diseases and found that IPF had a particularly high overlap with aging biology. IPF is a chronic disease that causes scarring in the lungs and a rapid decline in lung function. In contrast to the gradual loss of function seen in normal aging, IPF progresses more than five times faster. The authors highlight that IPF shares nearly all of the biological features associated with aging. These similarities make IPF a strong candidate for studying aging and testing therapies that target its underlying causes. The authors also discuss different therapies currently being developed for IPF that are also designed to address aging itself. These include drugs that clear senescent cells, activate telomerase to maintain chromosome health, or repair damaged signaling between cells. Some of these treatments, such as senolytic combinations and AI-discovered compounds like rentosertib, are already showing early promise in preclinical or clinical trials. In addition, the authors point out that IPF's fast progression and clearly measurable outcomes offer an advantage for clinical testing. If a therapy proves effective in IPF, it may also be useful for other conditions that share similar aging-related mechanisms, including diabetes, arthritis, and heart disease. This approach could accelerate drug development and reduce costs by focusing on therapies that target shared biological pathways. Overall, this perspective supports a shift in pharmaceutical research toward treating aging as an underlying cause of many chronic diseases. By positioning IPF as a model for aging-related drug development, the authors propose a strategic pathway for testing and expanding anti-aging therapies across a wide range of health conditions. DOI - https://doi.org/10.18632/aging.206301 Corresponding author - Alex Zhavoronkov – alex@insilico.com Video short - https://www.youtube.com/watch?v=p5ur7itzvSI Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Miti da sfatare
Italianità della pizza: poca | 528

Miti da sfatare

Play Episode Listen Later Sep 4, 2025 9:03


Oggi puntata pericolosa, ma ormai ci abbiamo fatto il callo. E inoltre ci possiamo nascondere dietro le spalle larghe dei nostri colleghi del podcast DOI che hanno autorevolezza da vendere sull’argomento. La pizza è italiana? No. Ma questo già si è detto e ridetto. Quello che forse non si sa è che in giro per il globo terracqueo è una nozione piuttosto diffusa, tanto che esiste l’effetto pizza. Cos’è l’effetto pizza? Ecco, quello lo scopriamo all’interno di questa puntata.See omnystudio.com/listener for privacy information.

Emergency Medical Minute
Episode 972: Hepatic Encephalopathy

Emergency Medical Minute

Play Episode Listen Later Sep 3, 2025 3:59


Contributor: Alec Coston, MD Educational Pearls: Hepatic encephalopathy (HE) is defined as a disruption in brain function that results from impaired liver function or portosystemic shunting. Manifests as various neurologic and psychiatric symptoms such as confusion, inattention, and cognitive dysfunction Although ammonia levels have historically been recognized as important criteria for HE, the diagnosis is ultimately made clinically. An elevated ammonia level lacks sensitivity and specificity for HE Trends in ammonia levels do not correlate with disease improvement or resolution A 2020 study published in the American Journal of Gastroenterology evaluated 551 patients diagnosed with hepatic encephalopathy and treated with standard therapy Only 60% of patients had an elevated ammonia level, demonstrating the limitations of ammonia levels However, a normal ammonia level in a patient with concern for HE should raise suspicion for other pathology. In patients with cirrhosis presenting with neuropsychiatric symptoms, consider HE as the diagnosis after excluding other potential causes of altered mental status (i.e., Seizure, infection, intracranial hemorrhage) The primary treatment is lactulose Works by acidifying the gastrointestinal tract. Ammonia (NH₃) is converted into ammonium (NH₄⁺), which is poorly absorbed and subsequently eliminated from the body Also exerts a laxative effect, further enhancing elimination References: Haj M, Rockey DC. Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. Am J Gastroenterol. 2020 May;115(5):723-728. doi: 10.14309/ajg.0000000000000343. PMID: 31658104. Lee F, Frederick RT. Hepatic Encephalopathy-A Guide to Laboratory Testing. Clin Liver Dis. 2024 May;28(2):225-236. doi: 10.1016/j.cld.2024.01.003. Epub 2024 Jan 30. PMID: 38548435. Vilstrup, Hendrik1; Amodio, Piero2; Bajaj, Jasmohan3,4; Cordoba, Juan1,5; Ferenci, Peter6; Mullen, Kevin D.7; Weissenborn, Karin8; Wong, Philip9. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60(2):p 715-735, August 2014. | DOI: 10.1002/hep.27210 Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs. 2019 Feb;79(Suppl 1):5-9. doi: 10.1007/s40265-018-1018-z. PMID: 30706420; PMCID: PMC6416238. Summarized by Ashley Lyons, OMS3 | Edited by Ashley Lyons & Jorge Chalit, OMS4 Get your tickets to Tox Talks Event, Sept 11, 2025: https://emergencymedicalminute.org/events-2/ Donate: https://emergencymedicalminute.org/donate/  

Voices of Wrestling Podcast Network
Open The Voice Gate - 25 Years of Naruki Doi!

Voices of Wrestling Podcast Network

Play Episode Listen Later Sep 3, 2025 92:22


Welcome back to Open The Voice Gate! Case (https://twitter.com/_inyourcase) and Mike (https://twitter.com/fujiiheya) are back with an update on the comings and goings of Dragongate.It's 25 Years of Naruki Doi as Dragongate returns to Nara (8/30) for his homecoming show and OTVG spend the episode celebrating the Runaway Muscle. Case and Mike ask some big questions about his career, discuss what makes Doi unique, and review two extra Doi matches, his Dream Gate defense against Koji Kanemoto in 2009 and his second Dream Gate title win against Ben-K!Match links can be found at voicesofwrestling.com or in the Open The Voice Gate channel in VOW's Discord!Our podcast provider, Red Circle, offers the listeners the option to sponsor the show. Click on “Sponsor This Podcaster” at https://redcircle.com/shows/open-the-voice-gate and you can donate a single time, or set up a monthly donation to Open The Voice Gate!Please Rate and Review Open The Voice Gate on the podcast platform of your choice and follow us on twitter at https://twitter.com/openvoicegate.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Mycopreneur
Robert Rush: Psilocybin Law

Mycopreneur

Play Episode Listen Later Sep 2, 2025 58:09


Today we're joined by leading Psilocybin and Psychedelic Law attorney Robert Rush of Rights and Reason Project. We discuss DOI and DOC, the potential rescheduling of Psilocybin from Schedule 1 to Schedule 2 under the Controlled Substances Act, psychedelic churches, the limits of decriminalization, the potential prohibition of 7-OH, and more. Please rate and review this episode wherever you're listening ( : Hosted on Acast. See acast.com/privacy for more information.

Aging-US
New Study Links Exosomes to Biological Aging

Aging-US

Play Episode Listen Later Sep 2, 2025 4:11


BUFFALO, NY — September 2, 2025 — A new #research paper featured on the #cover of Volume 17, Issue 8 of Aging (Aging-US) was #published on July 30, 2025, titled “Exosomes released from senescent cells and circulatory exosomes isolated from human plasma reveal aging-associated proteomic and lipid signatures.” In this study, led by first authors Sandip Kumar Patel and Joanna Bons, along with corresponding author Birgit Schilling from The Buck Institute for Research on Aging, researchers found that exosomes—tiny particles released by cells—carry molecular signatures that indicate both biological aging and cellular senescence. These signatures include proteins, lipids, and microRNAs associated with inflammation, oxidative stress, and tissue remodeling. The findings could enhance our understanding of biological aging and help in developing future anti-aging therapies. Senescence is a state in which cells stop dividing but remain metabolically active. These cells often release harmful substances, known collectively as the senescence-associated secretory phenotype (SASP), that can affect nearby tissues. This study shows that exosomes are an important component of this secretory profile. The researchers analyzed exosomes from senescent human lung cells and from the blood plasma of both young and older adults. They identified over 1,300 proteins and 247 lipids within these particles. Many of these molecules were significantly altered with age. “In parallel, a small human plasma cohort from young (20–26 years) and old (65–74 years) individuals revealed 1,350 exosome proteins and 171 plasma exosome proteins were altered in old individuals.” Exosomes from older individuals contained more inflammation-related proteins and fewer antioxidants, while those from senescent cells showed lipid changes associated with membrane integrity and cellular stress. These changes suggest that exosomes may play a role in spreading senescence to nearby cells, a process known as secondary senescence. The study also identified distinct patterns in microRNAs—small molecules that regulate gene expression—found in the blood of older adults. Some of these, including miR-27a and miR-874, have previously been associated with cognitive decline and chronic illnesses, highlighting their potential as biomarkers for biological aging. Although the study involved a limited number of samples, it provides strong early evidence that exosomes reflect the molecular changes associated with aging. By showing how these particles carry and possibly spread aging-related signals throughout the body, the research opens new possibilities for diagnosing and treating age-related diseases. DOI - https://doi.org/10.18632/aging.206292 Corresponding author - Birgit Schilling – bschilling@buckinstitute.org Video short - https://www.youtube.com/watch?v=tcyAZahw-g8 Keywords - aging, proteomics, senescence, exosomes, data-independent acquisitions Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

CHEST Journal Podcasts
Impact of COVID-19 on Pulmonary Critical Care Fellows In-Training Exam Performance: A National Study

CHEST Journal Podcasts

Play Episode Listen Later Sep 1, 2025 21:41


Mahmoud Alwakeel, MD, joins CHEST® Journal Podcast Moderator Alice Gallo De Moraes, MD, FCCP, to discuss his research into the impact of the COVID-19 pandemic on the performance of pulmonary and critical care medicine fellows on the in-training examination.  DOI: 10.1016/j.chest.2025.04.015 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

CHEST Journal Podcasts
To Make a Self: Exploring and Supporting Professional Identity Formation and Resilience of Intensivists Through Humanities

CHEST Journal Podcasts

Play Episode Listen Later Sep 1, 2025 25:44


Briseida Mema, MD, MHPE, joins CHEST® Journal Podcast Moderator Gretchen Winter, MD, to discuss her research into how critical care clinicians turn to the humanities to improve their overall well-being and reflect on the transformative experiences that disrupt their professional identity.    DOI: 10.1016/j.chest.2025.05.017 Disclaimer: The purpose of this activity is to expand the reach of CHEST content through awareness, critique, and discussion. All articles have undergone peer review for methodologic rigor and audience relevance. Any views asserted are those of the speakers and are not endorsed by CHEST. Listeners should be aware that speakers' opinions may vary and are advised to read the full corresponding journal article(s) for complete context. This content should not be used as a basis for medical advice or treatment, nor should it substitute the judgment used by clinicians in the practice of evidence-based medicine. 

Oncotarget
Blocking Protein Control Pathway Slows Rhabdomyosarcoma Growth in Mice

Oncotarget

Play Episode Listen Later Aug 29, 2025 3:58


BUFFALO, NY – August 29, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on August 29, 2025, titled “In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.” In this study led by first author Kristen Kwong and corresponding author Amit J. Sabnis from the Department of Pediatrics, Division of Oncology, University of California San Francisco, researchers discovered that disrupting the protein quality control system in cancer cells slows tumor growth in rhabdomyosarcoma (RMS), the most common pediatric soft tissue cancer. This finding points to a new strategy for treating high-risk childhood cancers that often resist current therapies. Rhabdomyosarcoma is a rare and aggressive cancer that primarily affects children and adolescents. Standard treatments like chemotherapy and radiation often have limited long-term success in high-risk cases. This study explored a different approach: targeting the cellular machinery that maintains protein quality, known as the proteostasis network. Cancer cells rely heavily on this system to survive stress caused by rapid growth and genetic instability. “To examine whether MAL3-101 or more drug-like proteostasis inhibitors represent a new therapeutic strategy for RMS, we screened proteostasis components that might recapitulate the effects of MAL3-101 in vivo.” The researchers first used a compound called MAL3-101 to disrupt protein control in RMS cells. They then identified which parts of the protein quality system were affected. Based on those findings, they searched for more drug-like compounds that could target the same pathways. They focused on a protein called p97, which plays a critical role in removing damaged or misfolded proteins. When they blocked p97 using a drug called CB-5083, the cancer cells could no longer manage internal stress and began to self-destruct. In both laboratory models and mice implanted with human RMS tumors, the treatment significantly slowed or stopped tumor growth. The drug triggered a stress response in the cells known as the unfolded protein response, which can lead to either recovery or programmed cell death. However, not all tumors responded the same way. Some resisted the treatment by activating a backup system called autophagy, which allows cells to recycle parts of themselves under stress. By comparing tumors that responded well to those that did not, the researchers found that higher autophagy activity could serve as a warning sign for resistance. This insight may help identify which patients are more likely to benefit from therapies that target protein quality control. While the results are promising, the drug's effectiveness depended on the tumor's genetic profile and how it handled stress. Combining p97 inhibition with other treatments or blocking alternative survival pathways like autophagy may improve outcomes. The researchers also noted the importance of developing safer and more targeted drugs to reduce side effects. This study opens new possibilities for personalized cancer treatment, particularly for children with aggressive or relapsed RMS. By weakening the systems that cancer cells depend on to survive, rather than only using toxic treatments to kill them, scientists aim to develop more effective and less harmful therapies for young patients. DOI - https://doi.org/10.18632/oncotarget.28764 Correspondence to - Amit J. Sabnis - amit.sabnis@ucsf.edu Video short - https://www.youtube.com/watch?v=YsdffTkXNRQ To learn more about Oncotarget, visit https://www.oncotarget.com. Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Obsgynaecritcare
144 Suzetrigine a discussion with Declan

Obsgynaecritcare

Play Episode Listen Later Aug 27, 2025 30:07


Hi everyone, This week Declan and I sit down to discuss a novel non opioid analgesic drug recently approved for use by the FDA, suzetrigine. What is it? How does it work? Why should we be interested in this new class of drugs and most importantly will it live up to it's hype? References Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain. Anesthesiology 142(6):p 989-991, June 2025. | DOI: 10.1097/ALN.0000000000005465 - Unfortunately this is not a free article but well worth a read if you can get to it through your hospital or college library. The accompanying podcast of this editorial is open access - follow the following link. podcast Suzetrigine Drug-Drug Interactions: Perioperative Anesthesia Considerations to Enhance Patient Safety

Aging-US
AUF1 Protein Plays Anti-Aging Role by Regulating Cellular Metabolism

Aging-US

Play Episode Listen Later Aug 27, 2025 3:41


BUFFALO, NY — August 27, 2025 — A new #research paper was #published in Volume 17, Issue 7 of Aging (Aging-US) on July 24, 2025, titled “RNA-binding protein AUF1 suppresses cellular senescence and glycolysis by targeting PDP2 and PGAM1 mRNAs.” In this study, Hyejin Mun, Chang Hoon Shin, Mercy Kim, Jeong Ho Chang, and Je-Hyun Yoon from the University of Oklahoma and Kyungpook National University investigated how changes in cellular metabolism contribute to aging. Their findings offer potential targets for therapies aimed at slowing or reducing the effects of aging. As cells age, they often lose their ability to divide and begin releasing harmful signals that damage nearby tissues. This process, called cellular senescence, is linked to many age-related diseases. A key feature of senescent cells is their altered metabolism, where they use more glucose and oxygen, even when oxygen levels are low. This leads to the production of inflammatory substances and fatty acids, which can accelerate tissue damage. The study examined how these metabolic changes are controlled at the molecular level. Researchers found that AUF1, a protein that binds to RNA, normally helps prevent aging by breaking down two enzymes involved in glucose metabolism: PGAM1 and PDP2. When AUF1 is missing or inactive, these enzymes build up. This causes the cell to produce more energy and inflammatory molecules, which are common features of senescent cells. “Our high throughput profiling of mRNAs and proteins from Human Diploid Fibroblasts (HDFs) revealed that the expression of pyruvate metabolic enzymes is inhibited by the anti-senescent RNA-binding protein (RBP) AUF1 (AU-binding Factor 1).” The team also identified another protein, MST1, which becomes active during cellular stress and aging. MST1 modifies AUF1 in a way that stops it from doing its protective job. As a result, PGAM1 and PDP2 accumulate, leading to faster aging of the cell. Experiments using human fibroblast cells and mouse models confirmed that higher levels of these enzymes are linked to stronger signs of cellular aging. These findings improve our understanding of how metabolism affects the aging process. They highlight the MST1-AUF1-PDP2/PGAM1 pathway as a key factor in the metabolic shift seen in aging cells. Since these enzymes and proteins are already known to be involved in other diseases, existing or future therapies might be used to block this pathway and reduce the effects of aging. This study offers a new direction for senotherapy—a field focused on treating or removing aging cells. By adjusting glucose metabolism through AUF1 and its targets, scientists believe it may be possible to slow aging or limit its effects on tissue function. More research is needed, but these insights could lead to new strategies for managing age-related diseases and promoting healthier aging. DOI - https://doi.org/10.18632/aging.206286 Corresponding authors - Jeong Ho Chang - jhcbio@knu.ac.kr, and Je-Hyun Yoon - jehyun-yoon@ouhsc.edu Video short - https://www.youtube.com/watch?v=Gbu6USUSkgg Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206286 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, AUF1, MST1, senescence, glycolysis To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Oncotarget
Behind the Study: R-spondin Family Roles in Metastatic Prostate Cancer

Oncotarget

Play Episode Listen Later Aug 26, 2025 7:06


Aiden Deacon from the University of Minnesota-Twin Cities, Minneapolis, discusses a research paper he co-authored that was published in Volume 16 of Oncotarget, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.” DOI - https://doi.org/10.18632/oncotarget.28758 Correspondence to - Justin Hwang - jhwang@umn.edu Video interview - https://www.youtube.com/watch?v=OXKhWWU1gnY Abstract This study investigates the R-spondin family of genes (RSPO1/2/3/4), a group of secreted proteins that act as Wnt regulators, and their subsequent role in advanced prostate cancer (PC). When evaluating transcriptomic data from primary and metastatic PC patients, we found that alterations in RSPO2 were more prevalent than in other RSPO family members or Wnt-regulating genes APC and CTNNB1. Further, we found that RSPO2 alterations in PCs were significantly associated with worse disease-free survival. Through our in silico modeling, RSPO2 exhibited strong positive associations with genes regulating epithelial-mesenchymal transition (EMT) and double-negative prostate cancer (DNPC), but had negative correlations with androgen receptor (AR) and AR-associated genes. Furthermore, 3D modeling of RSPO2 revealed structural differences between itself and other RSPOs. In cell lines, RSPO2 overexpression caused up-regulation of EMT pathways, including EMT-regulatory transcription factors ZEB1, ZEB2, and TWIST1. Conversely, this was not observed when CTNNB1 was overexpressed in the same models. These findings highlight that, in PC, RSPO2 functions as a unique member of the R-spondin family by promoting genes and signaling pathways associated with aggressive PC, and RSPO2 amplifications are associated with poor outcomes in PC patients. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28758 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, RSPO2, prostate cancer, Wnt signaling, genomics, therapeutics About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The Science of Motherhood
Ep 189. What Every Mum Should Know About Creatine, Hormones, and Recovery

The Science of Motherhood

Play Episode Listen Later Aug 25, 2025 25:05 Transcription Available


Motherhood takes it out of you. Physically. Mentally. Emotionally. And if you've ever felt like your energy's been zapped or your brain's running on 1%, you're not imagining it and you're definitely not alone.In this episode, Dr Renee White takes you on a deep dive into a surprising topic: creatine supplementation for women's health. That little white powder you've seen on gym shelves? It turns out, it might hold more benefits for mums than we ever realised.From brain fog and bloating to sleep, strength and recovery, Renee unpacks the latest research on how this naturally occurring compound can support women through every life stage. With her signature mix of science and soul, she breaks it down in a way that's easy to understand and incredibly relevant for busy, brilliant mums like you.You'll hear about:

Aging-US
Faster Biological Aging Linked to Cognitive Decline in Older Adults

Aging-US

Play Episode Listen Later Aug 25, 2025 3:48


BUFFALO, NY — August 26, 2025 — A new #research paper was #published in Volume 17, Issue 7 of Aging (Aging-US) on July 21, 2025, titled “Association of DNA methylation age acceleration with digital clock drawing test performance: the Framingham Heart Study.” In this study, led by first author Zexu Li from the Department of Anatomy and Neurobiology at Boston University Chobanian and Avedisian School of Medicine, and corresponding author Chunyu Liu from Boston University Chobanian and Avedisian School of Medicine and Boston University School of Public Health, researchers found that individuals with signs of faster biological aging had lower scores on a digital cognitive test taken seven years later. The findings suggest that the rate at which a person ages at the molecular level may be associated with how well their brain functions as they grow older. Using data from the Framingham Heart Study, the researchers examined the relationship between biological aging and cognitive health. They used DNA methylation (DNAm) patterns—chemical changes that occur in the DNA with aging, known as epigenetic aging—to estimate biological age acceleration, and used the digital Clock Drawing Test (dCDT) to assess cognitive performance. The dCDT is a computerized version of a traditional pen-and-paper test that evaluates memory, thinking speed, and motor control. It provides an overall score and measures performance in specific areas such as spatial reasoning and movement. Among 1,789 participants, higher levels of epigenetic age acceleration were associated with significantly lower cognitive scores, particularly those over age 65. Of all the epigenetic aging markers examined, the DunedinPACE measure showed the strongest association with reduced brain function in both younger and older adults. Other measures, such as Horvath and PhenoAge, were associated with lower scores only in older adults. Key areas affected included motor skills and spatial reasoning. The researchers also studied blood-based protein markers used in an aging measure called GrimAge. Two proteins, PAI1 and ADM, were closely associated with lower cognitive scores, especially in older individuals. These results suggest that declines in brain and motor functions may reflect broader aging-related changes throughout the body. “Digital cognitive measures displayed stronger associations with most DNAm aging metrics among older compared to younger participants, likely to reflect the cumulative and nonlinear age influences on both brain health and DNAm.” This study supports the idea that epigenetic age may be a more accurate predictor of cognitive decline than chronological age. The dCDT, which is easy to use, automated, and more precise than traditional tools, may help detect early signs of brain aging. When combined with DNAm measures, it could become a valuable part of regular health screenings. Overall, the findings provide strong evidence that faster biological aging is associated with cognitive decline. This research may lead to better ways of identifying and monitoring brain health in aging populations. DOI - https://doi.org/10.18632/aging.206285 Corresponding author - Chunyu Liu - liuc@bu.edu Video short - https://www.youtube.com/watch?v=4hyjDqnPs8w Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Communicable
Communicable E34: WHO's Fungal Priority Pathogens List

Communicable

Play Episode Listen Later Aug 24, 2025 50:24


Fungal infections and disease have long been overlooked in terms of healthcare burden, with poor diagnostics and limited options for treatment and management. In 2022, the WHO published its first Fungal Priority Pathogens List as an effort to establish a global prioritised framework that addresses unmet research and development needs in fungal disease and antifungal resistance, as well as guides public health action [1]. In this episode of Communicable, Angela Huttner and Josh Nosanchuk invite Hatim Sati (WHO), the project lead in creating this list, and Dimitrios Kontoyiannis (MD Anderson Cancer Center, Houston, Texas), a clinician researcher studying fungal diagnostics and antifungal discovery, for a candid discussion on the making of and relevance of such a list. Apart from reviewing the fungal pathogens, the conversation also covers limitations of the list, what to expect for the next iteration, contextualising the list in one's local region, and the impact the list has had already on research funding and public awareness.This episode was edited by Kathryn Hostettler and peer reviewed by Andrisa Xhaxha from Elbasan, Albania. ReferencesWHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Related podcast episodesCommunicable Episode 31: Climate change and fungal spread https://share.transistor.fm/s/db58f558 Communicable Episode 08: The nightmare series, part 1 – how to deal with Candida auris https://share.transistor.fm/s/c0616c4d Further reading Seidel D, et al. Impact of climate change and natural disasters on fungal infections. Lancet Microbe 2024. DOI: 10.1016/S2666-5247(24)00039-9Fisher MC and Denning DW. The WHO fungal priority pathogens list as a gamechanger. Nat Rev Microbiol 2023. DOI: 10.1038/s41579-023-00861-xShor E, et al. Tolerance and heteroresistance to echinocandins in Candida auris: conceptual issues, clinical implications, and outstanding questions. mSphere 2025. DOI: 10.1128/msphere.00161-25Panackal AA, et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis 2010. DOI: 10.1086/652761Lázár-Molnár E, et al. The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. PNAS 2008. DOI: 10.1073/pnas.0711918105Mashal M, “A potentially fatal fungal infections cropping up among India's Covid patients.” New York Times 2021. https://www.nytimes.com/2021/05/09/world/india-covid-mucormycosis.html Thevissen K, et al. International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. Crit Care 2020. DOI: 10.1186/s13054-020-2808-8Pappas PG, et al. Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27–30, 2018, Big Sky, Montana, a proposed global research agenda. Medical Mycology 2020. DOI: 10.1093/mmy/myaa034Hostettler K, et al. Communicable Episode 31: Climate change and fungal spread. CMI Communications 2025. DOI: 10.1016/j.cmicom.2025.105126

Dr. Chapa’s Clinical Pearls.
T for Her: Who, What, & How

Dr. Chapa’s Clinical Pearls.

Play Episode Listen Later Aug 21, 2025 31:13


In the last 2 episodes we covered new updates in menopausal hormone therapy. However, we did not address TESTOSTERONE use. This episode idea comes from one our podcast family members and good friend, Eric. Eric is 100% correct: Testosterone replacement, when done correctly, has come along way. When is this indicated? Is this endorsed by professional medical/endocrine groups? What's the dose? We have fun stuff to review, so listen in!1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4660-4666. doi: 10.1210/jc.2019-01603. PMID: 31498871; PMCID: PMC6821450.2. Sharon J. Parish, James A. Simon, Susan R. Davis, Annamaria Giraldi, Irwin Goldstein, Sue W. Goldstein, Noel N. Kim, Sheryl A. Kingsberg, Abraham Morgentaler, Rossella E. Nappi, Kwangsung Park, Cynthia A. Stuenkel, Abdulmaged M. Traish, Linda Vignozzi, International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women, The Journal of Sexual Medicine, Volume 18, Issue 5, May 2021, Pages 849–867, https://doi.org/10.1016/j.jsxm.2020.10.0093. Levy, Barbara MD, MSCP; Simon, James A. MD, MSCP. A Contemporary View of Menopausal Hormone Therapy. Obstetrics & Gynecology 144(1):p 12-23, July 2024. | DOI: 10.1097/AOG.00000000000055534. NAMS The 2022 hormone therapy position statement of The North American Menopause Society: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf

Aging-US
Impact of Cancer on Forensic DNA Methylation Age Estimation

Aging-US

Play Episode Listen Later Aug 21, 2025 3:41


BUFFALO, NY — August 21, 2025 — A new #research paper was #published in Volume 17, Issue 7 of Aging (Aging-US) on July 17, 2025, titled “The influence of cancer on a forensic age estimation tool.” In this study by Charlotte Sutter, Daniel Helbling, Cordula Haas and Jacqueline Neubauer from the Zurich Institute of Forensic Medicine, University of Zurich and Onkozentrum Zurich, the researchers investigated how cancer might affect the accuracy of forensic tools used to estimate a person's age from blood samples. DNA methylation is a natural chemical modification of DNA that changes with age. Forensic scientists can use these changes to predict someone's age from biological traces, such as blood found at a crime scene. However, medical conditions like cancer can alter these patterns and potentially reduce the accuracy of such predictions. This study investigated whether various cancer types influence the DNA markers used in age estimation. “Our study is among the first to show whether it might be necessary to account for the influence of cancer on forensic age estimation tools in order to enhance estimation accuracy as much as possible.” The researchers applied the VISAGE enhanced age estimation tool, a widely used DNA methylation-based method, to blood samples from 100 cancer patients and 102 healthy individuals. Age predictions in the control group were generally accurate, with small average errors. Patients with solid tumors, including breast and lung cancers, showed only slightly less accurate results. In contrast, individuals with blood cancers, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), sometimes had large errors, with ages overestimated by as much as 50 years. Despite these few extreme cases, the study found that cancer does not typically have a strong impact on the accuracy of this forensic tool. Most cancer patients, even those undergoing treatment, had DNA methylation patterns similar to those of healthy individuals. The researchers found no consistent differences based on cancer type, stage, or treatment, except in isolated cases involving aggressive forms of cancer. The findings support the continued use of current forensic age estimation methods. While aggressive cancers may occasionally affect prediction accuracy, such cases are rare. The researchers suggest noting these conditions as a possible factor in unusually large errors, without requiring changes to standard practice. This study provides valuable information about how health conditions, such as cancer, may influence DNA-based age estimation. It strengthens confidence in the reliability of forensic age prediction tools, even when applied to individuals with a medical history of cancer. DOI - https://doi.org/10.18632/aging.206281 Corresponding author - Cordula Haas - cordula.haas@irm.uzh.ch Video short - https://www.youtube.com/watch?v=lcpwE50O4ss Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206281 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, forensic age, estimation age prediction, cancer, DNA methylation, age acceleration To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Oncotarget
Aramchol Boosts Regorafenib Effectiveness in Gastrointestinal Tumors

Oncotarget

Play Episode Listen Later Aug 19, 2025 3:35


BUFFALO, NY – August 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on August 19, 2025, titled “The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells in vitro and in vivo.” In this study, led by first authors Laurence Booth and Michael R. Booth, along with corresponding author Paul Dent from Virginia Commonwealth University, researchers investigated how aramchol, a drug originally developed for liver disease, works with the cancer drug regorafenib in gastrointestinal (GI) tumor cells. They found that the combination is effective, especially in tumor cells with a specific genetic variant. The combined approach offers a potential new strategy for treating liver and colon cancers. Gastrointestinal cancers, such as liver and colon cancer, are serious global health challenges. Regorafenib, already approved for cancer treatment, can have limited impact and frequently causes side effects. Aramchol, a drug developed to treat fatty liver disease, affects how cancer cells process fats and energy. In this study, researchers tested whether combining these two drugs could improve GI cancer treatment, both in cells and mouse models. The results showed that the drug combination killed liver and colorectal cancer cells more effectively than either drug alone. In animal models, mice with human liver tumors had slower tumor growth, without showing signs of weight loss or other toxicity. The researchers also found that aramchol and regorafenib work together to block important survival pathways inside cancer cells. This combination was especially effective in cells with a genetic variant called ATG16L1 T300, which is more common in people of African ancestry. The treatment triggered stress responses in the cancer cells and disrupted key proteins required for survival. It also activated autophagy, a natural recycling process that clears out damaged parts, eventually leading to cancer cell death. “Aramchol interacted with the multi-kinase inhibitors sorafenib, regorafenib or lenvatinib, to kill GI tumor cells, with regorafenib exhibiting the greatest effect.” Aramchol is currently in clinical trials for fatty liver disease and has a well-established safety profile, while regorafenib is already FDA-approved for cancer treatment. Together, their combination could advance fast into clinical testing for patients with GI cancers. However, researchers note that additional studies are needed to support the launch of early-phase clinical trials. Altogether, this study may offer a more effective and less toxic alternative to current treatments for GI cancers. It also highlights the role of genetic variants in shaping treatment response, suggesting that future therapies could be more precisely tailored to each patient's unique genetic profile. DOI - https://doi.org/10.18632/oncotarget.28762 Correspondence to - Paul Dent - paul.dent@vcuhealth.org Video short - https://www.youtube.com/watch?v=5saAqsqxi-Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28762 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, macroautophagy, flux; ER stress, aramchol, regorafenib To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Stuff You Missed in History Class
Estevanico, aka Mustapha al-Azemmour

Stuff You Missed in History Class

Play Episode Listen Later Aug 18, 2025 42:41 Transcription Available


Estevanico was a translator and guide, and was probably the first person of any race from outside the Americas to enter what’s now Arizona and New Mexico – which happened in 1539. Research: Birzer, Dedra McDonald and J.M.H. Clark. “Esteban Dorantes.” Peoples of the Historical Slave Trade. Journal of Slavery and Data Preservation. https://enslaved.org/fullStory/16-23-92882/ Birzer, Dedra McDonald. "Esteban." Oxford African American Studies Center. May 31, 2013. Oxford University Press. Date of access 30 Jul. 2025, https://oxfordaasc.com/view/10.1093/acref/9780195301731.001.0001/acref-9780195301731-e-34375 Chipman, Donald E. and Robert S. Wedd. “How Historical Myths Are Born...... And Why They Seldom Die.” The Southwestern Historical Quarterly , January, 2013. https://www.jstor.org/stable/24388345 Clark, J.M.H. "Esteban the African ‘Estebanico’." Oxford African American Studies Center. May 31, 2017. Oxford University Press. Date of access 30 Jul. 2025, https://oxfordaasc.com/view/10.1093/acref/9780195301731.001.0001/acref-9780195301731-e-73900 Docter, Mary. “Enriched by Otherness: The Transformational Journey of Cabeza de Vaca.” Christianity and Literature , Autumn 2008, Vol. 58, No. 1. Via JSTOR. https://www.jstor.org/stable/44313875 "Estevanico (1500-1539)." Encyclopedia of World Biography, Gale, 1998. Gale Academic OneFile, link.gale.com/apps/doc/A148426031/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=41f83344. Accessed 28 July 2025. Flint, Richard. “Dorantes, Esteban de.” New Mexico Office of the State Historian. Via archive.org. https://web.archive.org/web/20110728080635/http://www.newmexicohistory.org/filedetails.php?fileID=464 Gordon, Richard A. “Following Estevanico: The Influential Presence of an African Slave in Sixteenth-century New World Historiography.” Colonial Latin American Review Vol. 15, No. 2, December 2006. Gordon-Reed, Annette. “Estebanico’ s America.” The Atlantic. June 2021. Herrick, Dennis. “Esteban.” University of New Mexico Press. 2018. Project MUSE. https://muse.jhu.edu/book/60233. Ilahiane, Hsain. “Estevan de Dorantes, Estevanico: The First Moroccan and African Explorer of the American Southwest.” Southwest Center. Via YouTube. 2/21/2024. https://www.youtube.com/watch?v=RLm0BsFDfvk Ilahiane, Hsain. “Estevan De Dorantes, the Moor or the Slave? The other Moroccan explorer of New Spain.” The Journal of North African Studies, 5:3, 1-14, DOI: 10.1080/13629380008718401 Ladd, Edmund J. “Zuni on the Day the Men in Metal Arrived.” From The Coronado Expedition to Tierra Nueva. Shirley Cushing Flint and Richard Flint, eds. University Press of Colorado. 2004. https://muse.jhu.edu/book/3827 Logan, Rayford. “Estevanico, Negro Discoverer of the Southwest: A Critical Reexamination.” Phylon (1940-1956), Vol. 1, No. 4 (4th Qtr., 1940). Via JSTOR. https://www.jstor.org/stable/272298 Sando, Joe S. “Pueblo nations: eight centuries of Pueblo Indian history.” Santa Fe, N.M. : Clear Light. 1992. Shields, E. Thomson. "Esteban." Oxford African American Studies Center. December 01, 2006. Oxford University Press. Date of access 30 Jul. 2025, https://oxfordaasc-com.proxy.bostonathenaeum.org/view/10.1093/acref/9780195301731.001.0001/acref-9780195301731-e-17021 Simour, Lhoussain. “(De)slaving history: Mostafa al-Azemmouri, the sixteenth-century Moroccan captive in the tale of conquest.” European Review of History—Revue europe´enne d’histoire, 2013 Vol. 20, No. 3. http://dx.doi.org/10.1080/13507486.2012.745830 Smith, Cassander L. “Beyond the Mediation: Esteban, Cabeza de Vaca's ‘Relación’ , and a Narrative Negotiation.” Early American Literature , 2012, Vol. 47, No. 2. Via JSTOR. https://www.jstor.org/stable/41705661 See omnystudio.com/listener for privacy information.

Psychedelics Today
PT 620 - Kat Murti – Students for Sensible Drug Policy, Meta Censorship, and the Fight for Science

Psychedelics Today

Play Episode Listen Later Aug 18, 2025 80:00


In this episode, Joe Moore is joined by Kat Murti, Executive Director of Students for Sensible Drug Policy (SSDP), the largest youth-led network working to end the war on drugs. SSDP organizes at the campus, local, state, federal, and international levels, with more than 100 chapters across the U.S. and sister organizations worldwide. Kat shares her personal journey into drug policy reform, from witnessing DEA raids on AIDS patients in the 1990s to fighting for civil liberties as a student at UC Berkeley. She explains how SSDP empowers young people to challenge outdated laws and promote policies rooted in compassion, scientific evidence, and human rights. Topics Discussed The War on Drugs as a War on Us: Kat's early realizations about the drug war's racism, injustice, and destruction of civil liberties. Her Path to SSDP: From working on California's Prop 19 cannabis campaign to serving on SSDP's board and eventually becoming Executive Director. Meta Censorship Campaign: Why Meta's restrictions on drug education and harm reduction content harm communities, and how SSDP is organizing public pressure to protect freedom of information online. Forced Institutionalization & Executive Orders: Kat critiques recent federal moves to expand forced treatment, cuts to naloxone training programs, and the misguided use of tariffs as “solutions” to the overdose crisis. The Fight Against DEA Scheduling of DOI & DOC: Why these research chemicals are vital to neuroscience and medicine, how SSDP challenged the DEA in court, and what's at stake for future research. Illogical Drug Policy & Careerism: How prohibition persists due to political incentives, propaganda, and entrenched bureaucratic interests. Building a Better Future: Realigning incentive structures, embracing harm reduction, and supporting community-based solutions to drug use. Key Takeaways The war on drugs is deeply racist, anti-science, and erodes civil liberties. Meta's censorship of harm reduction information actively endangers lives. Forced treatment doesn't work—addressing social conditions and providing safe housing does. DOI and DOC, rarely if ever used recreationally, are critical to medical research, and scheduling them would halt decades of progress. Real reform means both ending prohibition and creating environments where people feel supported, connected, and empowered. Links & Resources Students for Sensible Drug Policy (SSDP): ssdp.org Kat Murti on Twitter/X: @KatMurti Kat Murti on Instagram: @KittyRevolution SSDP Petition against Meta Censorship: ssdp.org

Frankly Speaking About Family Medicine
Patient Portal SOS! Strategies to Tame the In-Basket - Frankly Speaking Ep 446

Frankly Speaking About Family Medicine

Play Episode Listen Later Aug 18, 2025 11:38


Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-446 Overview: Overwhelmed by in-basket tasks? Discover a practical scheduling intervention that gives you time during the clinic day to manage portal messages. Learn how “portal practice slots” can reduce burnout, improve workflow, and empower you to advocate for changes that support sustainable, high-quality primary care. Episode resource links: J Gen Intern Med. DOI: 10.1007/s11606-025-09582-8 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Pri-Med Podcasts
Patient Portal SOS! Strategies to Tame the In-Basket - Frankly Speaking Ep 446

Pri-Med Podcasts

Play Episode Listen Later Aug 18, 2025 11:38


Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-446 Overview: Overwhelmed by in-basket tasks? Discover a practical scheduling intervention that gives you time during the clinic day to manage portal messages. Learn how “portal practice slots” can reduce burnout, improve workflow, and empower you to advocate for changes that support sustainable, high-quality primary care. Episode resource links: J Gen Intern Med. DOI: 10.1007/s11606-025-09582-8 Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

The Flipping 50 Show
Running vs Walking for Fast Fat Loss in Menopause

The Flipping 50 Show

Play Episode Listen Later Aug 15, 2025 61:24


Fast fat loss in menopause is not really the goal. Let's be realistic and say this right out of the gate. Fast fat loss is a myth.  You may, however, drop inflammation fairly quickly with the right type of exercise.    Part 1: The Fat Burning Fundamentals Let's start with the basics. When we talk about fat burning during exercise, we need to understand two key concepts:  Percentage of Fat Used for Fuel  Total Calories Burned Here's something surprising: At rest, we burn about 85% fat for fuel. Your body is already a fat-burning machine when you're sitting on the couch!  Here's where it gets interesting.. During low-intensity exercise like walking, you burn a higher percentage of fat for fuel, but you're burning calories at a slower rate overall. During high-intensity exercise like running, you burn a lower percentage of fat for fuel, but you're torching calories much faster. Part 2: The EPOC Effect - Your Metabolic Afterburn EPOC or Excess Post-Exercise Oxygen Consumption, but I like to call it your metabolic afterburn. This is the energy your body continues to burn AFTER your workout is over. High-intensity exercise creates a significant EPOC effect. Your body keeps burning calories for hours after you finish your workout as it works to restore oxygen levels, repair tissues, and return to its normal state. It's like your metabolism stays revved up long after you've stopped moving. Low-intensity exercise produces minimal EPOC. Once you stop walking, your metabolism pretty quickly returns to baseline. You burned calories during the activity, but the party's over when you stop. This is where high-intensity exercise starts to look really appealing for fat loss. You're not just burning calories during the workout - you're creating a metabolic boost that lasts for hours. Know the Best Strategy for Fast Fat Loss in Menopause May Surprise You Part 3: Sprints vs Steady-State Running - The Game Changer When we compare running at a slow to moderate pace versus doing sprint intervals, the sprint work wins hands down for fat loss.  Sprint intervals create a massive EPOC effect. Your body works harder to recover from intense bursts, burning calories long after you're done. Sprint intervals are incredibly effective at burning both total body fat AND visceral belly fat. The beauty of sprints is that you can get incredible results in much less time. A 15-20 minute sprint session can be more effective for fat loss than an hour of steady jogging. For busy women in menopause, this efficiency factor is huge. Part 4: The Cortisol Connection - Why This Matters in Menopause Now we need to talk about cortisol, because this is where things get really important for women in menopause. High-intensity exercise creates a greater rise in cortisol compared to low-intensity exercise. This isn't necessarily bad! This cortisol response is actually normal and necessary. It's how your body releases blood sugar to be used as fuel and creates energy for exercise. Low-intensity exercise like walking creates little rise in cortisol. Comfortable walking, dancing, yoga, or tai chi often actually REDUCE cortisol levels. The problem isn't the acute cortisol rise from exercise itself. The problem is chronic elevated cortisol combined with high-intensity exercise when your system is already overloaded. If your stress bucket is already overflowing from work, relationships, poor sleep, and hormonal changes, adding high-intensity exercise makes it spill over. When cortisol is chronically elevated, it can sabotage your adrenal function and ultimately affect your thyroid. This is particularly relevant during menopause when our hormone systems are already in flux.  Choosing the Right Cardio for Fast Fat Loss in Menopause The Hot Not Bothered is open for enrollment as this episode goes live. If you need support getting a start, restart or reset, now is the time! Learn More Here   Part 5: The Real Running vs Walking Debate Here's where I want to challenge the traditional running versus walking debate. Maybe it's less about the percentage of fat burned for fuel and more about not burning yourself out. Let me give you a practical example from my own experience: Walking at a 5.0 pace on the treadmill is NOT comfortable for me. It's an effort - I'm breathing hard, I'm sweating, I'm working. But jogging at 5.8? That's actually quite slow for running. It's likely harder on my knees while not really providing enough impact to benefit my bone density. Here's a crucial point: Every time you run - meaning both feet leave the ground - you add four times your body weight in impact to your knee joints. Yet ironically, this repetitive impact isn't the kind of stimulus that optimally benefits bone density once you do it regularly. While jumping and purposeful impact exercises do provide bone density benefits, repetitive exercise loads like jogging don't create additional stress - they just create more of the same stress. So sometimes, a challenging walk might actually give you better results than an easy jog, with less wear and tear on your joints. The sad myth about running vs walking is that it will result in fast fat loss in menopause - or any time for that matter. Smarter Workouts for Fast Fat Loss in Menopause — Without Burnout Part 6: When Your Body Is Telling You to Slow Down Chronic cortisol elevation is often linked to inadequate recovery - particularly nutrition - than to workout intensity itself. If you're on a chronically low-carbohydrate or low-calorie diet, you may experience prolonged cortisol elevations regardless of your exercise. When your body lacks fuel, it compensates by releasing more cortisol to break down fat, muscle, and even bone tissue for energy. Chronic cortisol is more likely under these conditions: Too much too soon (occasional overreaching isn't a problem, but repeated overreaching is) Undereating before, during, or after exercise Lack of rest time between workouts for repair Inadequate sleep Planned diet or fasting state Lower intensity workouts may work better because you're not eating enough, not sleeping enough, or not managing your overall stress load. The biggest problem? Not eating enough. Going too low carb. Making statements like "my body loves this" when it's giving you signs you're exhausted, holding onto weight, or failing to gain muscle. No, it doesn't love it. Part 7: Making the Right Choice for YOU How do you decide between running and walking, or between steady-state and sprint work? Assess your current stress load: How's your sleep? Are you eating enough, especially carbohydrates? How are your energy levels throughout the day? Are you seeing the results you want? If you're well-rested, well-fed, and managing stress effectively, higher intensity work including sprints is incredibly effective for fat loss. If you're stressed, under-fueled, or sleep-deprived, walking or other lower-intensity activities is better right now.  That's not settling for less - that's being smart about working WITH your body instead of against it. The best exercise program is what you can do consistently while feeling energized and strong, not depleted and exhausted. Fast Fat Loss in Menopause Differs for Every Body in Every Stage Part 8: Practical Applications For sprint work: Start with just 1-2 sprint sessions per week. These could be 15-30 second all-out efforts followed by as much time needed for recovery, repeated 4-6 times. This gives you maximum fat-burning benefit with minimal time investment. For steady-state work: If you choose to run steadily, make sure it's at an intensity that's appropriately challenging. If you choose to walk, don't be afraid to make it challenging - hills, speed, or resistance can all increase the demand. For recovery: Always prioritize adequate nutrition and sleep. Your results happen during recovery, not just during the workout. Listen to your body's feedback. If you're consistently tired, holding onto weight despite "doing everything right," or feeling burnt out, it might be time to dial down the intensity and focus on recovery. Conclusion The bottom line? Both running and walking can be effective for fat loss, but the devil is in the details.  Sprint work offers incredible efficiency and targets visceral fat effectively. Steady-state cardio has its place, especially when recovery demands are high. The key is matching your exercise intensity to your body's current capacity for stress and recovery. During menopause, this becomes even more critical as our hormone systems are already adapting to change. Your exercise program should energize you, not exhaust you. It should work with your lifestyle, not against it. And it should leave you feeling strong and capable, not depleted and overwhelmed.   Remember, there's no real magic trick for fast fat loss in menopause. However, you can get there faster - sometimes by slowing down and sometimes by sprinting. But always by weight lifting.    References for Fast Fat Loss in Menopause:  Psychoneuroendocrinology. 2022, PMID: 35777076. Front Public Health, 2019, PMID: 31921741. Experimental Physiology, 2020, PMID: 32613697. Journal of Exercise Science & Fitness, 2023, PMID: 37927356. Diabetes & Metabolism, 2016, DOI: 10.1016/j.diabet.2016.07.031.   Other Episodes You Might Like: Previous Episode - Take Up Space: A Perimenopause BodyBuilder on Her Strength Journey Next Episode - The New Menopause Therapy: Confessions of a Femme Fatale More Like This What's Better Running or Walking for Midlife Fat Loss (and why) 8 Ways to Make Walking in Menopause MORE Beneficial   Resources:  Join the Hot, Not Bothered! Challenge to learn why timing matters and why what works for others is not working for you. Use Flipping 50 Scorecard & Guide to measure what matters with easy at-home self-assessment test you can do in minutes. Don't know where to start? Book your Discovery Call with Debra.

Pediheart: Pediatric Cardiology Today
Pediheart Podcast Replay #258: The Effects Of Race And Insurance Status On Waitlist Outcomes In Pediatric Heart Transplantation

Pediheart: Pediatric Cardiology Today

Play Episode Listen Later Aug 15, 2025 30:50 Transcription Available


In this week's replay episode from 3 years ago, we delve into the world of pediatric heart transplantation and the impact that race or insurance status may have on outcomes. What are the factors that explain worse outcomes for black children waiting for a heart transplant? How is the PHTS Racial Disparity Taskforce working to reduce inequities in this field? What role does insurance status have on these outcomes? We speak with noted heart failure and transplantation expert, Dr. Neha Bansal who is Associate Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai about this recent PHTS multicenter study.DOI: 10.1016/j.healun.2022.12.002

Oncotarget
FDA-Approved MI Cancer Seek Test Enhances Tumor Profiling for Precision Oncology

Oncotarget

Play Episode Listen Later Aug 15, 2025 4:13


BUFFALO, NY – August 15, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on August 13, 2025, titled “Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay.” In this study, first authors Valeriy Domenyuk and Kasey Benson, along with corresponding author David Spetzler from Caris Life Sciences in Irving, Texas, introduce MI Cancer Seek, an FDA-approved test designed to deliver comprehensive tumor profiling. MI Cancer Seek demonstrated strong concordance with other FDA-approved companion diagnostics and serves as a powerful tool to guide treatment decisions in both adult and pediatric cancer patients. Cancer remains one of the most complex and diverse diseases to treat. With many targeted therapies currently FDA-approved, selecting the right one for a specific patient requires detailed genetic insights. MI Cancer Seek addresses this need by analyzing both DNA and RNA from a single tumor sample. The tool identifies key biomarkers linked to FDA-approved treatments for several major cancers, including breast, lung, colon, melanoma, and endometrial cancers. One of the most significant strengths of MI Cancer Seek is its ability to deliver accurate and reliable results from minimal tissue input (50 ng). Even when analyzing formalin-fixed paraffin-embedded samples, which are widely used but often degraded, the test maintained high levels of accuracy. It successfully detected important genetic alterations such as PIK3CA, EGFR, BRAF, and KRAS/NRAS mutations and measured tumor mutational burden (TMB) and microsatellite instability (MSI), both of which are key indicators for immunotherapy response. In clinical comparisons, the test achieved over 97% agreement with other FDA-approved diagnostic tools, confirming its reliability in detecting critical biomarkers. Notably, it showed near-perfect accuracy in identifying MSI status in colorectal and endometrial cancers. The researchers also demonstrated that the test maintains precision across different lab conditions and varying DNA input levels, confirming its robustness for routine clinical use. Beyond its role as a companion diagnostic, MI Cancer Seek incorporates additional features developed under its predecessor, MI Tumor Seek Hybrid. These include detection of homologous recombination deficiency, structural variants, and cancer-related viruses. It also includes advanced tools such as the Genomic Probability Score for identifying the tissue of origin in cancers of unknown primary, as well as a gene signature to guide first-line chemotherapy in colorectal cancer. “One limitation to be considered is the low PPA for ERBB2 CNA detection.” By offering deeper genetic insights from a single, small sample, MI Cancer Seek has the potential to streamline diagnostics, reduce testing costs, and connect patients to effective therapies more quickly. As precision medicine continues to expand, this assay stands out as a comprehensive and efficient solution for meeting the evolving needs of modern oncology. DOI - https://doi.org/10.18632/oncotarget.28761 Correspondence to - David Spetzler - dspetzler@carisls.com Video short - https://www.youtube.com/watch?v=D4hd2FxCYY8 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Strength In Knowledge
Still Not 100%? Using Dual-Task Testing to Detect Hidden Post-Concussion Deficits

Strength In Knowledge

Play Episode Listen Later Aug 13, 2025 9:49 Transcription Available


In this 10-minute episode, Zach Baker, DPT, and Asher Roberts, DPT, unpack a 2024 study by Hashida et al. that sheds light on an often-overlooked issue: athletes may still have lingering deficits even after being cleared to return to play. Learn how a simple, feasible dual-task test can reveal residual post-concussion impairments that standard assessments might miss—and how this can impact your return-to-play decisions in the clinic.Referenced Study:Hashida et al. (2024). Feasible dual-task detects residual post-concussion deficits after return-to-play.DOI: 10.1080/02640414.2024.2447666

Classroom Caffeine
Season 5 Reflections & Season 6 Preview

Classroom Caffeine

Play Episode Listen Later Aug 12, 2025 9:03 Transcription Available


Send us a textHost Lindsay Persohn reflects on Season 5's journey through literacy education, where conversations explored evolving reading debates, strategies for supporting diverse learners, vocabulary development, and content-specific literacies. Lindsay also shares a recap of research presentations and publications related to podcasting by the Classroom Caffeine team.Season 6 of the show promises two compelling special series. The first examines the transformative power of graduate studies for educators, featuring candid conversations with professionals who've pursued advanced degrees and discovered new pathways for growth and impact. These discussions illuminate how continued education shapes not just career opportunities but also classroom practice and student outcomes.The second series spotlights the Spencer Foundation-supported "Stories to Live By" project, exploring how Florida teachers help students navigate climate challenges through place-based learning. As communities face hurricanes, flooding, and environmental uncertainty, these educators work at the critical intersection of climate science, political tensions, and students' lived experiences—empowering young people to think critically and act practically in response to ongoing change.Publications mentioned in this episode:Persohn, L., Burger, L., & Geren, K. V. (2025). Pod Clubs for professional community: learning, conversation, and relationships. Professional Development in Education, 1–21. https://doi.org/10.1080/19415257.2025.2514703Branson, S.M., Persohn, L., Burger, L., Geren, K.V., & Robertson Stemme, M. (2025). Collaborative Connections in ‘Pod Clubs' for Professional Learning. In C. Bohem, T. Canfer, & C. Salazar (Eds.) in Podcasting & Education: Concepts, Communities & Case Studies. Routledge.Persohn, L., & Branson, S. (2025). Scholarly Podcasting for Research Dissemination: A Scoping Review. SAGE Open, 15(1). https://doi.org/10.1177/21582440241311694 (Direct link to available publication: https://journals.sagepub.com/doi/10.1177/21582440241311694.)Persohn, L. & Branson, S.M. (2024). Broadening Legitimacy of Scholarly Podcasting as Knowledge Dissemination: Metrics, Opportunities and Considerations. Publishing Research Quarterly, 40(3). DOI: https://doi.org/10.1007/s12109-024-10005-5Connect with Classroom Caffeine at www.classroomcaffeine.com or on Instagram, Facebook, Twitter, and LinkedIn.

You Are Not Broken
330. Does Your Physician's Gender Matter?

You Are Not Broken

Play Episode Listen Later Aug 10, 2025 54:30


This week I'm joined by Dr. Christopher Wallis, a urologist and researcher whose groundbreaking work shows something that might just change the way you think about surgery and medicine: patients are more likely to survive—and thrive—when operated on by a female surgeon and physician. We dive deep into the data, including studies across multiple countries and specialties, and unpack the consistent 5% reduction in 30-day mortality rates when the surgeon is a woman. Dr. Wallis also discusses how female anesthesiologists impact outcomes, why communication and trust matter so much in surgery, and how female physicians are often unfairly penalized for complications. This episode is more than stats—it's about challenging the system, confronting bias, and empowering both patients and physicians to make more informed, conscious choices. If you've ever wondered whether gender matters in medicine, or how we can build a better, fairer healthcare system—don't miss this one. We cover: ✔️ Why female surgeons lead to better outcomes ✔️ The role of bias and the “rigged” system women in medicine face ✔️ What patients should look for in a surgical team ✔️ Why systemic change is long overdue in healthcare Let's get into it. DOI:10.1097/SLA.0000000000006217 http://dx.doi.org/10.1136/bmj-2023-075484 https://uofturology.ca/directory/faculty/wallis-chris/ Want more honest, empowering conversations like this one?⁠⁠⁠Preorder my Next Book⁠⁠⁠ share this episode, and leave a review to help others find this important work. Let's stop leaving women out of the conversation—especially when it comes to sex, health, and healing. Listen to my Tedx Talk: ⁠⁠⁠⁠⁠⁠⁠⁠⁠Why we need adult sex ed⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠Take my Adult Sex Ed Master Class:⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠My Website⁠⁠⁠⁠⁠⁠⁠⁠⁠ Interested in my sexual health and hormone clinic? ⁠⁠⁠⁠⁠⁠⁠⁠⁠Waitlist is open⁠⁠⁠⁠⁠⁠⁠⁠ Thanks to our sponsor ⁠⁠⁠⁠⁠⁠⁠⁠⁠Midi Women's Health⁠⁠⁠⁠⁠⁠⁠⁠⁠. Designed by midlife experts, delivered by experienced clinicians, covered by insurance.Midi is the first virtual care clinic made exclusively for women 40+. Evidence-based treatments. Personalized midlife care.⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.joinmidi.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

PICU Doc On Call
Emerging Neurologic Autoimmune Disorders (MOGAD) in the PICU

PICU Doc On Call

Play Episode Listen Later Aug 10, 2025 27:42


Welcome to "PICU Doc on Call," the podcast where real cases meet real expertise at the bedside! Join Dr. Monica Gray, Dr. Pradip Kamat, and Dr. Rahul Damania as they unravel the mysteries of pediatric critical care. In today's episode, our team dives into the compelling case of a previously healthy seven-year-old girl who arrives with seizures, right arm weakness, and sudden respiratory failure. Together, they'll break down the diagnosis and management of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, also known as MOGAD. This autoimmune demyelinating disorder can challenge even the most seasoned clinicians. Tune in as our experts walk you through the clinical features, essential diagnostic workup, and the critical importance of early immunosuppressive therapy. Whether you're at the bedside or on the go, this episode is packed with practical pearls and a multidisciplinary approach to recognizing and treating acute pediatric neuroimmunological emergencies in the PICU. Let's get started!Show Highlights:Presentation of a complex pediatric case involving a seven-year-old girl with new-onset seizures and acute respiratory failureDiscussion of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) as an autoimmune demyelinating disorderOverview of the clinical presentation and diagnostic criteria for autoimmune encephalitisImportance of a broad differential diagnosis, including infectious and autoimmune causes, in pediatric patients with seizures and neurological deficitsDiagnostic approach involving MRI, lumbar puncture, and antibody testing for MOGADManagement strategies for MOGAD, including stabilization, seizure control, and immunosuppressive therapyNeurocritical care considerations for monitoring and treating elevated intracranial pressureLong-term management challenges and the need for multidisciplinary care in pediatric patients with MOGADDiscussion of potential outcomes and the risk of relapse in children with MOGAD.Emphasis on the importance of early and comprehensive diagnostic testing to avoid misdiagnosisReferences:Fuhrman & Zimmerman - Pediatric Critical Care 6th Edition, Chapter 64Gole S, Anand A. Autoimmune Encephalitis. [Updated 2023 Jan 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK578203/Salama S, Khan M, Pardo S, Izbudak I, Levy M. MOG antibody-associated encephalomyelitis/encephalitis. Mult Scler. 2019 Oct;25(11):1427-1433. doi: 10.1177/1352458519837705. Epub 2019 Mar 25. PMID: 30907249; PMCID: PMC6751007Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. J Clin Neurol. 2016 Jan;12(1):1-13. doi: 10.3988/jcn.2016.12.1.1. PMID: 26754777; PMCID: PMC4712273.Fisher KS, Illner A, Kannan V. Pediatric neuroinflammatory diseases in the intensive care unit. Semin Pediatr Neurol. 2024 Apr;49:101118. Doi: 10.1016/j.spen.2024.101118. Epub 2024 Feb 1. PMID: 38677797.Hébert J, Muccilli A, Wennberg RA, Tang-Wai DF. Autoimmune Encephalitis and Autoantibodies: A Review of Clinical Implications. J Appl Lab Med. 2022 Jan 5;7(1):81-98. Doi: 10.1093/jalm/jfab102. PMID: 34996085.Lopez JA, Denkova M, Ramanathan S, Dale RC, Brilot F. Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease. Clin Transl Immunology. 2021 Jul 26;10(7):e1316. doi: 10.1002/cti2.1316. PMID: 34336206; PMCID: PMC8312887.

Everything Hertz
193: The pop-up journal

Everything Hertz

Play Episode Listen Later Aug 7, 2025 59:03


Dan and James chat about a a new 'pop-up journal' concept for addressing specific research questions. They also answer a listener question from a journal grammar editor and discuss a new PNAS article on paper mills Links * The pop-up journal (https://popupjournal.com) * The episode (https://everythinghertz.com/58) where Dan's wife went into labor * The PNAS paper mill paper (https://www.pnas.org/doi/10.1073/pnas.2420092122) * A blog post (https://reeserichardson.blog/2025/08/04/a-do-or-die-moment-for-the-scientific-enterprise/) from the PNAS paper lead author, Reese Richardson. * The Nature piece (https://www.nature.com/articles/d41586-025-02446-5) on the paper Social media links - Dan on Bluesky (https://bsky.app/profile/dsquintana.bsky.social) - James on Bluesky (https://bsky.app/profile/jamesheathers.bsky.social) - Everything Hertz on Bluesky (https://bsky.app/profile/hertzpodcast.bsky.social) Citation Quintana, D. S., & Heathers, J. (2025, August 7). 193: The pop-up journal, Everything Hertz [Audio podcast], DOI: 10.17605/OSF.IO/2ZMQ7

Surviving Your Shift, Building Responder Wellness
What Is Peer Support and Why It Matters

Surviving Your Shift, Building Responder Wellness

Play Episode Listen Later Aug 7, 2025 24:54 Transcription Available


What is peer support—and why does it matter so much in high-stress jobs? In this episode, you'll learn how it works, what it's not, and why it's saving lives on the front lines.Ever wonder what peer support actually is—and why it seems like everyone's talking about it lately?Too many departments are using the term without really knowing what it means—or how to make it work. Worse, some well-meaning programs fail because they weren't clearly defined or supported.And if you're thinking of starting a team—or you already have one that feels stuck—there's a good chance the problem isn't the people. It's the lack of clarity, training, or purpose.In this episode, I break down what peer support is, what it isn't, and why it matters more than ever for first responders, medical professionals, and anyone working in a high-stress profession.BY THE TIME YOU FINISH LISTENING, YOU'LL DISCOVER:What peer support is—and why it's not the same as being a good friendThe difference between Crisis Intervention Peer Support (CISM) and Comprehensive Peer SupportThe practical steps to build or improve a peer support program that actually helpsWhether you're just getting started or trying to level up your existing team, this episode gives you a roadmap to do it right.OTHER LINKS MENTIONED IN THIS EPISODE:Share this episodeSchedule a free discovery callQPR Suicide Intervention TrainingCISM and Peer Support Training InfoCitations:Jessica N. Jeruzal, Lori L. Boland, Monica S. Frazer, Jonathan W. Kamrud, Russell N. Myers, Charles J. Lick & Andrew C. Stevens (2018): Emergency Medical Services Provider Perspectives on Pediatric Calls: A Qualitative Study, Prehospital Emergency Care, DOI: 10.1080/10903127.2018.1551450(2025, May 7). A Qualitative Study on the Design and Implementation of a First Responder Operational Stress Injury Clinic. PubMed Central. Retrieved August 2, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12059418(ND). A Day Like No Other: A Case Study of the Las Vegas Mass Shooting. New Mexico Department of Homeland Security & Emergency Management. Retrieved August 2, 2025, from https://nmdhsem2024-cf.rtscustomer.com/wp-content/uploads/2024/03/Las-Vegas-Mass-Shooting-Case-Study-by-NV-Hospital-Association-2018.pdf(2025, January 15). Frank Leto—Success Stories from FDNY's Counseling Service Unit | S5 E3. First Responder Center for Excellence. Retrieved August 2, 2025, from https://www.respondertv.com/s5-e3-success-stories-from-fdnys-counseling-service-unit-witIf you're receiving value from this podcast, consider becoming a monthly supporter—your gift helps me keep producing these practical episodes. Become a supporter today. Connect with Bart LinkedIn: linkedin.com/in/bartleger Facebook Page: facebook.com/survivingyourshift Website: survivingyourshift.com Want to find out how I can help you build a peer support program in your organization or provide training? Schedule a no-obligation call or Zoom meeting with me here.

Beekeeping Today Podcast
[Bonus] Short: Dr. Dewey Caron - Mite Management and Bee Learning Breakthroughs

Beekeeping Today Podcast

Play Episode Listen Later Aug 6, 2025 18:15


In this Beekeeping Today Podcast Short, Dr. Dewey Caron returns with his monthly audio postcard—this time focused on August mite management and a remarkable discovery about honey bee learning. Dewey reminds beekeepers that August is a critical month to monitor and treat for varroa mites before their populations explode. He shares updates on new and emerging treatments, including Norroa (a dsRNA-based biopesticide), Mite Bee Gone (L-glutamic acid strips), and Apivar 2.0, as well as best practices for applying oxalic acid extended release strips like VarroxSan. Dewey shifts from mites to mind-blowing research on bee communication. Drawing on the work of Dr. James Nieh, he explains how the waggle dance—used by bees to communicate foraging locations—is learned through social exposure, similar to how birds and humans acquire language. This study, featured in Science, marks the first demonstration of social learning in insect spatial communication. This episode blends practical mite management insights with inspiring science, all in under 20 minutes. Stay proactive. Plan your treatments. And appreciate the depth of honey bee intelligence. Links & Resources: Overviews of mite control: Beekeeping Today Podcast Shorts on Varroa Treatments: https://www.beekeepingtodaypodcast.com/p/varroa/ University of Massachusetts Extension Flyer on Varroa: https://www.mass.gov/doc/varroa-mite-ipm-brochure-english/download NY Bee Wellness presentation of Dr David Peck of BetterBee https://www.youtube.com/watch?v=N4ALfqq3GT8 Veto Pharma (makers fo Apivar 2.0 and Apiguard and Varroa Easy Check sampling device) has 2 informative, nicely illustrated flyers: Integrated varroa mite management throughout the seasons - https://forms.newsletter.veto-pharma.com/5eff419fb85b5317165fde16/yBL1IKRLTxShk0jw3QcfXw/7eYSzqY0RyqLN5ngRfmpDw/form.html Varroa Mite Biology - https://forms.newsletter.veto-pharma.com/5eff419fb85b5317165fde16/O7Cp5mGSSpmFPTRAUADdmA/0DTVnqNkR32oXrlA35HsEA/form.html VitaBee Health products (makers of VarroxSan, VARROCheck sampling jar and Vita feed supplements) - https://www.vita-europe.com/beehealth/wp-content/uploads/vita-beekeeping-guide.pdf MiteBeeGone: https://mitebeegone.com/ Additional Resouces Thomas A. O'Shea-Wheller, Asia Hall, Kirsty Stainton, Victoria Tomkies, Giles E. Budge, Selwyn Wilkins and Ben Jones. 2025. A large-scale study of Varroa destructor treatment adherence in apiculture. Entomologia Generalis.DOI: 10.1127/entomologia/2024/2758 Reports on oxalic acid effectiveness from Canada Quebec: https://academic.oup.com/jinsectscience/article/24/3/14/7683875 and Ontario:https://www.mdpi.com/2076-0817/14/8/724 Science article on social learning in Dance Language https://labs.biology.ucsd.edu/nieh/papers/DongScience.pdf YouTube presentation at https://www.youtube.com/watch?v=elWNc_1qm60   Brought to you by Betterbee – your partners in better beekeeping. ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com Copyright © 2025 by Growing Planet Media, LLC

Stuff You Missed in History Class
Beatrice Kenner and Midred Smith: Sister Inventors

Stuff You Missed in History Class

Play Episode Listen Later Jul 30, 2025 40:52 Transcription Available


Beatrice Kenner’s inventions were focused largely on making life easier and less annoying for herself and the people around her, including period products. Mildred Smith’s invention was about family, and it grew from her disability after she developed multiple sclerosis. Research: “Deaths.” Evening Star. 11/27/1956. https://www.newspapers.com/image/869672410/ “Mildred E. Smith.” Obituary. Washington Post. 8/19/1993. https://www.washingtonpost.com/archive/local/1993/08/19/n-hugh-mcdiarmid-dies-at-86/beab0fdf-9aec-4ac1-bd0a-cfcef223f1fa/ Byram, W.F. and R.P. Phronebarger. “Current Supply System for Electric Railways.” U.S. Patent 1,134,871. 4/6/1915. Coren, Ashleigh, et al. “The Many Inventions of Beatrice Kenner.” Side Door. Smithsonian Institution. 4/6/2022. https://www.si.edu/sidedoor/many-inventions-beatrice-kenner Davidson, S.N. “Pants Presser.” U.S. Patent 1,088,329. Hambrick, Arlene. “Biographies of Black Female Scientists and Inventors: An Interdisciplinary Middle School Curriculum Guide. ‘What Shall I Tell My Children Who Are Black?’” Graduate School of the University of Massachusetts. Doctor of Education Dissertation. 1993. DOI: 10.7275/14756666 Hodal, Kate. “Cloth, cow dung, cups: how the world's women manage their periods.” The Guardian. 3/14/2019. https://www.theguardian.com/global-development/2019/apr/13/cloth-cow-dung-cups-how-the-worlds-women-manage-their-periods Jeffrey, Laura S. “Amazing American Inventors of the 20th Century.” Enslow Publishers, Inc.. 1996, 2013. Kenner, Mary Beatrice. “Busch Traffic.” Daily Press. 11/12/1984. https://www.newspapers.com/image/234268212/ Kijowska, Wiktoria. “Sanitary suspenders to Mooncups: a brief history of menstrual products.” Victoria and Albert Museum. https://www.vam.ac.uk/articles/a-brief-history-of-menstrual-products King, Helen. “From rags and pads to the sanitary apron: a brief history of period products.” The Conversation. 4/25/2023. https://theconversation.com/from-rags-and-pads-to-the-sanitary-apron-a-brief-history-of-period-products-203451 O’Sullivan, Joan. “Disease Victim Creates Game.” The Orange Leader. 10/8/1982. https://www.newspapers.com/image/1008083420/ Ravey, Julia and Dr. Ella Hubber. “Unstoppable: Mary Beatrice Davidson Kenner.” Unstoppable. BBC. 6/17/2024. https://www.bbc.co.uk/sounds/play/w3ct5rmq Sluby, Patricia Carter. “African American Brilliance.” Tar heel junior historian [2006 : fall, v.46 : no.1]. https://digital.ncdcr.gov/Documents/Detail/tar-heel-junior-historian-2006-fall-v.46-no.1/3700440?item=5369779 Smith, Mildred E. “Family Relationships Card Game.” U.S. Patent 4,230,321. 10/28/1980. https://ppubs.uspto.gov/api/pdf/downloadPdf/4230321 Tsjeng, Zing. “Forgotten Women: The Scientists.” Cassell Illustrated. 2018. Tsjeng, Zing. “The Forgotten Black Woman Inventor Who Revolutionized Menstrual Pads.” Vice. 3/8/2018. https://www.vice.com/en/article/mary-beatrice-davidson-kenner-sanitary-belt/ Washington Afro American. “Jabbo Kenner Leads Boys to Clean Life.” 11/15/1947. https://www.newspapers.com/image/1042304374/ Washington Daily News. “Mrs. Kenner Is In Clover.” 6/2/1958. https://www.newspapers.com/image/1042178951/ See omnystudio.com/listener for privacy information.